



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07H 21/00, C07K 2/00, 14/52, A61K 31/70, 31/715, 38/00, 39/00	A2	(11) International Publication Number: WO 99/62923 (43) International Publication Date: 9 December 1999 (09.12.99)
(21) International Application Number: PCT/US99/12538 (22) International Filing Date: 4 June 1999 (04.06.99) (30) Priority Data: 60/088,310 5 June 1998 (05.06.98) US 09/324,191 1 June 1999 (01.06.99) US (71) Applicant (for all designated States except US): DYNAVAX TECHNOLOGIES CORPORATION [US/US]; Suite 100, 717 Potter Street, Berkeley, CA 94710 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): SCHWARTZ, David [US/US]; 1544 Valleda Lane, Encinitas, CA 92024 (US). (74) Agents: POLIZZI, Catherine, M. et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: IMMUNOSTIMULATORY OLIGONUCLEOTIDES WITH MODIFIED BASES AND METHODS OF USE THEREOF (57) Abstract <p>Immunomodulatory oligonucleotide compositions are disclosed. These oligonucleotides comprise an immunostimulatory hexanucleotide sequence comprising a modified cytosine. These oligonucleotides can be administered in conjunction with an immunomodulatory peptide or antigen. Methods of modulating an immune response upon administration of the oligonucleotide comprising a modified immunostimulatory sequence are also disclosed.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

5 CROSS-REFERENCE TO RELATED APPLICATIONS

10 STATEMENT OF RIGHTS TO INVENTIONS MADE UNDER FEDERALLY
SPONSORED RESEARCH

TECHNICAL FIELD

20 BACKGROUND ART

30 The Th1 subset may be particularly suited to respond to viral infections and intracellular pathogens because it secretes IL-2 and IFN- γ , which activate CTLs. The Th2 subset may be more suited to respond to free-living bacteria and helminthic parasites and may mediate allergic reactions, since IL-4 and IL-5 are known to induce IgE production

and eosinophil activation, respectively. In general, Th1 and Th2 cells secrete distinct patterns of cytokines and so one type of response can moderate the activity of the other type of response. A shift in the Th1/Th2 balance can result in an allergic response, for example, or, alternatively, in an increased CTL response.

5 Immunization of a host animal against a particular antigen has been accomplished traditionally by repeatedly vaccinating the host with an immunogenic form of the antigen. While most current vaccines elicit effective humoral (antibody, or "Th2-type") responses, they fail to elicit cellular responses (in particular, major histocompatibility complex (MHC) class I-restricted CTL, or "Th1-type" responses) which are generally absent or weak. For
10 many infectious diseases, such as tuberculosis and malaria, Th2-type responses are of little protective value against infection. Moreover, antibody responses are inappropriate in certain indications, most notably in allergy where an antibody response can result in anaphylactic shock. Proposed vaccines using small peptides derived from the target antigen and other currently used antigenic agents that avoid use of potentially infective
15 intact viral particles, do not always elicit the immune response necessary to achieve a therapeutic effect. The lack of a therapeutically effective human immunodeficiency virus (HIV) vaccine is an unfortunate example of this failure.

Protein-based vaccines typically induce Th2-type immune responses, characterized by high titers of neutralizing antibodies but without significant cell-mediated immunity. In
20 contrast, intradermal delivery of "naked", or uncomplexed, DNA encoding an antigen stimulates immune responses to the antigen with a Th1-type bias, characterized by the expansion of CD4⁺ T cells producing IFN- γ and cytotoxic CD8⁺ T cells. Manickan et al. (1995) *J. Immunol.* 155:250-265; Xiang et al. (1995) *Immunity* 2:129-135; Raz et al. (1995) *Proc. Natl. Acad. Sci. USA* 93:5141-5145; and Briode et al. (1997) *J. Allergy Clin.*
25 *Immunol.* 99:s129. Injection of antigen-encoding naked DNA reproducibly induces both humoral and cellular immune responses against the encoded antigens. Pardoll and Beckerleg (1995) *Immunity* 3:165-169. DNA vaccines can provide a new approach to infectious disease prophylaxis. See, for instance, Dixon (1995) *Bio/Technology* 13:420 and references cited therein.

30 Certain types of DNA, without being translated, have been shown to stimulate immune responses. Bacterial DNA induces anti-DNA antibodies in injected mice, as well as cytokine production by macrophage and natural killer (NK) cells. Pisetsky (1996) *J.*

Immunol. 156:421-423; Shimada et al. (1986) *Jpn. J. Cancer Res.* 77:808-816; Yamamoto et al. (1992a) *Microbiol. Immunol.* 36:983-997; and Cowdery et al. (1996) *J. Immunol.* 156:4570-4575.

B cell and NK cell activation properties of bacterial DNA have been associated with short (6 base pair hexamer) sequences that include a central unmethylated CpG dinucleotide. Yamamoto et al. (1992a); and Krieg et al. (1995) *Nature* 374:546-549. Oligonucleotides comprising a CpG sequence flanked by two 5' purines and two 3' pyrimidines have been shown to be most potent in B cell and NK cell stimulation. For example, when a variety of oligonucleotides comprising hexamers were tested for their ability to augment the NK cell activity of mouse spleen cells, the most immunogenic hexamers included AACGTT, AGCGCT, GACGTC. Yamamoto et al. (1992b) *J. Immunol.* 148:4072-4076. In a study in which B cell activation was measured in response to oligonucleotides, the most stimulatory hexamer sequences (e.g., AACGTC, AACGTT, GACGTC, GACGTT) also matched the sequence of 5'-purine, purine, CG, pyrimidine, pyrimidine-3'. Krieg et al. (1995).

Bacterial DNA stimulated macrophages to produce IL-12 and TNF- α . These macrophage-produced cytokines were found to induce the production of IL-12 and IFN- γ from splenocytes. Halpern et al. (1996) *Cell. Immunol.* 167:72-78. *In vitro* treatment of splenocytes with either bacterial DNA or CpG containing oligonucleotides induced the production of IL-6, IL-12 and IFN- γ . Klinman et al. (1996) *Proc. Natl. Acad. Sci. USA* 93:2879-2883. Production of all of these cytokines is indicative of induction of a Th1-type immune response rather than a Th2-type response.

Todate, no clear consensus has been reached on the sequences both necessary and sufficient of immune stimulation. A recent study which examined induction of NK activity in response to CpG containing-oligonucleotides suggested that the unmethylated CpG motif was necessary but not sufficient for oligonucleotide induction of NK lytic activity. Ballas et al. (1996) *J. Immunol.* 157:1840-1845. Sequences flanking the CpG appeared to influence the immunostimulatory activity of an oligonucleotide. Immunostimulatory activity of immunostimulatory sequences appears to be independent of adenosine-methylation, and whether the nucleotide is single or double-stranded. See, for example, Tokunaga et al. (1989) *Microbiol. Immunol.* 33:929; Tokunaga et al. (1992) *Microbiol.*

Immunol. 36:55-66; Yamamoto et al. (1992b); Messina et al. (1993) *Cell. Immunol.* 147:148-157; and Sato et al. (1996) *Science* 273:352-354. Oligonucleotide length also does not seem to be a factor, as double-stranded DNA 4 kb long (Sato et al. (1996)) or single-stranded DNA as short as 15 nucleotides in length (Ballas et al. (1996)) elicited immune responses; though if oligonucleotide length was reduced below 8 bases or if the DNA was methylated with CpG methylase, immunostimulatory activity was abolished. Krieg et al. (1995).

Allergic responses, including those of allergic asthma, are characterized by an early phase response, which occurs within seconds to minutes of allergen exposure and is characterized by cellular degranulation, and a late phase response, which occurs 4 to 24 hours later and is characterized by infiltration of eosinophils into the site of allergen exposure. Specifically, during the early phase of the allergic response, activation of Th2-type lymphocytes stimulates the production of antigen-specific IgE antibodies, which in turn triggers the release of histamine and other mediators of inflammation from mast cells and basophils. During the late phase response, IL-4 and IL-5 production by CD4⁺ Th2 cells is elevated. These cytokines appear to play a significant role in recruiting eosinophils into site of allergen exposure, where tissue damage and dysfunction result.

Antigen immunotherapy for allergic disorders involves the subcutaneous injection of small, but gradually increasing amounts, of antigen. Such immunization treatments present the risk of inducing IgE-mediated anaphylaxis and do not address the cytokine-mediated events of the allergic late phase response.

Vaccination with certain DNA containing immunostimulatory motifs induces an immune response with a Th1-type bias. For example, mice injected intradermally with *Escherichia coli* (*E. coli*) β -galactosidase (β -Gal) in saline or in the adjuvant alum responded by producing specific IgG1 and IgE antibodies, and CD4⁺ cells that secreted IL-4 and IL-5, but not IFN- γ , demonstrating that the T cells were predominantly of the Th2 subset. However, mice injected intradermally (or with a tyne skin scratch applicator) with plasmid DNA (in saline) encoding β -Gal and containing an ISS responded by producing IgG2a antibodies and CD4⁺ cells that secreted IFN- γ , but not IL-4 and IL-5, demonstrating that the T cells were predominantly of the Th1 subset. Moreover, specific IgE production by the plasmid DNA-injected mice was reduced 66-75%. Raz et al. (1996) *Proc. Natl.*

Acad. Sci. USA 93:5141-5145. In general, the response to naked DNA immunization is characterized by production of IL-2, TNF α and IFN- γ by antigen-stimulated CD4⁺ T cells, which is indicative of a Th1-type response. This is particularly important in treatment of allergy and asthma as shown by the decreased IgE production.

5 In another example, the presence of an immunostimulatory sequence, such as the palindromic hexamer AACGTT, in an antigen-encoding plasmid vector injected intradermally prompted the production of large amounts of IFN- α , IFN- β and IL-12. Sato et al. (1996). IFN- α plays a role in the differentiation of naive T cells toward a Th1-type phenotype, antagonizes Th2 cells, inhibits IgE synthesis, promotes IgG2a production and
10 induces a Th1 phenotype of antigen-specific T cell clones. IL-12 promotes IFN- γ production by T cells and favors maturation of Th1 cells.

It would be useful in treatment of a wide variety of indications to be able to specifically enhance the Th1-type response to a particular antigen while down-regulating the Th2-type response to the same antigen. Treatment or palliation of these indications
15 includes, but is not limited to, tumor therapy, treatment of allergic disorders and induction of a vigorous cellular immune response. The present invention provides compositions comprising oligonucleotide sequences that can be employed in these contexts.

All of the cited literature included in the preceding section, as well as the cited literature included in the following disclosure, are hereby incorporated by reference.

20

DISCLOSURE OF THE INVENTION

In one embodiment, the ISS comprises a hexameric sequence or hexanucleotide comprising a central CG sequence, where the C residue is modified by the addition to C-5 and/or C-6 with an electron-withdrawing moiety. Preferably, the electron-withdrawing
25 group is a halogen or halogen-containing ligand. Suitable halogens include chlorine, bromine and fluorine. Suitable halogen-containing ligands include, but are not limited to, 5-bromocytosine, 5-fluorocytosine, 5-chlorocytosine, and 5-trifluoromethyl cytosine.

In another embodiment, the modified ISS comprises the general sequence 5'-Purine, Purine, Cytosine, Guanine, Pyrimidine, Pyrimidine-3'. More preferably, the modified ISS
30 comprises the general sequences selected from the group consisting of AACGTC,

AACGTT, AGCGTC, AGCGCT, AGCGTT, GACGTC, GACGTT, and GGCGTT. The modified ISS can also comprise any other physiologically acceptable modification.

In another embodiment, the modified ISS comprises the general sequence 5'-Purine, Purine, Cytosine, Guanine, Pyrimidine, Pyrimidine, Cytosine, Cytosine-3'. More preferably, the modified ISS comprises a sequence selected from the group consisting of AACGTTCC and GACGTTCC.

In another embodiment, the modified ISS comprises the general sequence 5'-Purine, Purine, Cytosine, Guanine, Pyrimidine, Pyrimidine, Cytosine, Guanine-3'. More preferably, the modified ISS comprises a sequence selected from the group consisting of AACGTTTCG and GACGTTTCG.

In another embodiment, the modified ISS comprises the sequence of SEQ ID NO:2.

In another embodiment, the modified ISS comprises the sequence of SEQ ID NO:6.

In another embodiment, the modified ISS comprises the sequence of SEQ ID NO:7.

In another embodiment, the invention provides an immunomodulatory composition comprising a modified ISS and further comprising an antigen.

In another embodiment, the invention provides an immunomodulatory composition comprising a modified ISS in conjunction with a member of the group of immunomodulation facilitators consisting of co-stimulatory molecules, cytokines, chemokines, targeting protein ligand, a trans-activating factor, a peptide, or a peptide comprising a modified amino acid.

In another embodiment, the invention provides an immunomodulatory composition comprising a modified ISS, an antigen and an adjuvant.

The present invention also provides for a method of modulating an immune response comprising the administration of an amount of a modified ISS effective to induce an immune response. Preferably, modulation of an immune response comprises induction of a Th1-type immune response.

In another embodiment, the invention provides methods of treating an individual in need of immune modulation comprising administration of a composition comprising a modified ISS.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 illustrates the structure of 5-cytosine substituted CpG dinucleotide.

Fig. 2 presents a graph depicting the level of IL-6 found in the culture supernatant of splenocytes after exposure to oligonucleotides for 48 hours. See Table 1 for identification of oligonucleotides.

Fig. 3 presents a graph depicting the level of IL-12 found in the culture supernatant of splenocytes after exposure to oligonucleotides for 48 hours. See Table 1 for identification of oligonucleotides.

Fig. 4 presents a graph showing the efficacy of various oligonucleotides comprising modified cytosines to stimulate proliferation of splenocytes. Cell proliferation determined after 48 hours in culture. See Table 1 for identification of oligonucleotides.

MODES FOR CARRYING OUT THE INVENTION

We have discovered modified oligonucleotide sequences capable of modulating an immune response. Such oligonucleotide sequences comprise an immunostimulatory sequence (ISS) comprising a CG dinucleotide in which the C residue is modified by addition to C-5 and/or C-6 of an electron-withdrawing moiety ("modified ISS"). Compositions of the subject invention comprise the modified ISS oligonucleotide alone or in conjunction with an immunomodulatory agent, such as a peptide, an antigen and/or an additional adjuvant. When the same cytosine is methylated, all immunostimulatory activity of the oligonucleotide is lost. Some of the modified ISS have approximately the same, if not greater, immunostimulatory activity relative to the same sequence without a modified base.

Previously described immunostimulatory sequences have comprised a hexamer sequence with a central CpG dinucleotide. The ISS of the present invention comprises any immunostimulatory sequence having the CpG dinucleotide where the C-5 and/or C-6 positions of the C is modified with an electron-withdrawing group. Preferably, the modified ISS contains an hexanucleotide sequence which comprises 5'-purine, purine, cytosine, guanine, pyrimidine, pyrimidine-3'. More preferably, the modified ISS contains an hexanucleotide sequence which comprises 5'-AACGTT-3' or 5'-GACGTT-3'. More preferably, the modified ISS contains an octanucleotide sequence which comprises the previously described hexamer and two additional nucleotides 3' of the hexamer. Preferably, the modified ISS octamer comprises 5'-purine, purine, cytosine, guanine, pyrimidine, pyrimidine, cytosine, guanine-3' or the modified ISS octamer comprises 5'-

purine, purine, cytosine, guanine, pyrimidine, pyrimidine, cytosine, cytosine-3'. More preferably, the modified ISS octanucleotide comprises 5'-GACGTTTCG-3' or 5'-GACGTTCC-3'. Still more preferably, the modified ISS octanucleotide comprises 5'-AACGTTTCG-3' or 5'-AACGTTCC-3'.

5 The ISS oligonucleotide of the present invention can comprises any other physiologically acceptable modified nucleotide base. Preferably, in such compositions, the cytosine in the third position from the 5' end can be substituted with a cytosine analog, preferably 5-bromocytidine, fluorinated cytosine, or chlorinated cytosine.

10 The invention also provides a method and compositions for a general stimulation of an immune response through the adjuvant-like effect of an administered modified ISS.

 The present invention also provides methods for the use of a modified ISS in conjunction with an antigen in stimulation of an immune response. Preferably, as used in such methods, the modified ISS provides an adjuvant-like activity in the generation of a Th1-type immune response to the antigen.

15 Preferably, the immune response stimulated according to the invention is biased toward the Th1-type phenotype and away from the Th2-type phenotype. With reference to the invention, stimulating a Th1-type immune response can be determined *in vitro* or *ex vivo* by measuring cytokine production from cells treated with modified ISS as compared to those treated without modified ISS. Methods to determine the cytokine production of cells include those methods described herein and any known in the art. The type of cytokines produced in response to modified ISS treatment indicate a Th1-type or a Th2-type biased immune response by the cells. As used herein, the term "Th1-type biased" cytokine production refers to the measurable increased production of cytokines associated with a Th1-type immune response in the presence of a stimulator as compared to production of such cytokines in the absence of stimulation. Examples of such Th1-type biased cytokines include, but are not limited to, IL-2, IL-12, and IFN- γ . In contrast, "Th2-type biased cytokines" refers to those associated with a Th2-type immune response, and include, but are not limited to, IL-4, IL-5, IL-10 and IL-13. Cells useful for the determination of ISS activity include cells of the immune system, primary cells isolated from a host and/or cell lines, preferably APCs and lymphocytes, even more preferably macrophages and T cells.

30 Stimulating a Th1-type immune response can also be measured in a host treated with a modified ISS-antigen composition and can be determined by any method known in

the art including, but not limited to: (1) a reduction in levels of IL-4 measured before and after antigen-challenge; or detection of lower (or even absent) levels of IL-4 in a modified ISS-antigen treated host as compared to an antigen-primed, or primed and challenged, control treated without modified ISS; (2) an increase in levels of IL-12, IL-18 and/or IFN (α , β or γ) before and after antigen challenge; or detection of higher levels of IL-12, IL-18 and/or IFN (α , β or γ) in a modified ISS-antigen treated host as compared to an antigen-primed or, primed and challenged, control treated without modified ISS; (3) IgG2a antibody production in a modified ISS-antigen treated host as compared to a control treated without modified ISS; and/or (4) a reduction in levels of antigen-specific IgE as measured before and after antigen challenge; or detection of lower (or even absent) levels of antigen-specific IgE in a modified ISS-antigen treated host as compared to an antigen-primed, or primed and challenged, control treated without modified ISS. A variety of these determinations can be made by measuring cytokines made by APCs and/or lymphocytes, preferably macrophages and/or T cells, *in vitro* or *ex vivo* using methods described herein or any known in the art. Methods to determine antibody production include any known in the art.

The Th1-biased cytokine induction which occurs as a result of modified ISS administration produces enhanced cellular immune responses, such as those performed by NK cells, cytotoxic killer cells, Th1 helper and memory cells. These responses are particularly beneficial for use in protective or therapeutic vaccination against viruses, fungi, protozoan parasites, bacteria, allergic diseases and asthma, as well as tumors.

General Techniques

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry and immunology, which are within the skill of the art. Such techniques are explained fully in the literature, such as, "Molecular Cloning: A Laboratory Manual", second edition (Sambrook et al., 1989); "Oligonucleotide Synthesis" (M.J. Gait, ed., 1984); "Animal Cell Culture" (R.I. Freshney, ed., 1987); "Methods in Enzymology" (Academic Press, Inc.); "Handbook of Experimental Immunology" (D.M. Weir & C.C. Blackwell, eds.); "Gene Transfer Vectors for Mammalian Cells" (J.M. Miller & M.P. Calos, eds., 1987); "Current Protocols in Molecular Biology" (F.M. Ausubel et al.,

eds., 1987); "PCR: The Polymerase Chain Reaction", (Mullis et al., eds., 1994); and "Current Protocols in Immunology" (J.E. Coligan et al., eds., 1991).

Compositions comprising the Modified ISS

5 A composition of the subject invention is a modified ISS which is capable of eliciting a desired immune response upon administration. The term "modified ISS" as used herein refers to oligonucleotide sequences that effect a measurable immune response and comprise a CG dinucleotide in which the C residue is modified by addition to C-5 and/or C-6 of an electron-withdrawing moiety. Examples of measurable immune responses
10 include, but are not limited to, antigen-specific antibody production, secretion of cytokines, activation or expansion of lymphocyte populations such as NK cells, CD4⁺ T lymphocytes, CD8⁺ T lymphocytes, B lymphocytes, and the like. Preferably, the modified ISS sequences preferentially activate the Th1-type response.

 This oligonucleotide can be administered in conjunction with an
15 immunomodulatory molecule, such as an antigen or an immunostimulatory peptide, as described herein. The modified oligonucleotide of the composition contains at least one modified immunostimulatory oligonucleotide sequence ("modified ISS").

 The modified ISS preferably comprises a CpG containing sequence, as illustrated in Fig. 1. More preferably, the modified ISS comprises an oligomer of the hexanucleotide
20 sequence 5'-Purine, Purine, CG, Pyrimidine, Pyrimidine-3'. More preferably the modified ISS comprises a hexanucleotide sequence selected from the group consisting of AACGTT and GACGTT. More preferable still, the modified ISS comprises an oligomer of the octanucleotide sequence 5'-Purine, Purine, CG, Pyrimidine, Pyrimidine, Cytosine, Cytosine-3' or the octanucleotide sequence 5'-Purine, Purine, CG, Pyrimidine, Pyrimidine,
25 Cytosine, Guanine-3'. Even more preferably, the modified ISS comprises an octanucleotide selected from the group consisting of AACGTTCC, AACGTTCCG, GACGTTCC and GACGTTCCG.

 Where the oligonucleotide comprises an RNA sequence, the modified ISS preferably comprises a single-stranded or double-stranded sequence selected from the
30 group consisting of AACGUU, GACGUU, AACGUUCC, AACGUUCG, GACGUUCC, and GACGUUCG.

In accordance with the present invention, the oligonucleotide contains at least one modified ISS, and can contain multiple modified ISSs. The modified ISSs can be adjacent within the oligonucleotide, or they can be separated by additional nucleotide bases within the oligonucleotide.

5 As used interchangeably herein, the terms "oligonucleotide" and "polynucleotide" include single-stranded DNA (ssDNA), double-stranded DNA (dsDNA), single-stranded RNA (ssRNA) and double-stranded RNA (dsRNA), modified oligonucleotides and oligonucleosides or combinations thereof. The oligonucleotide can be linearly or circularly configured, or the oligonucleotide can contain both linear and circular segments.

10 The ISS can be of any length greater than 6 bases or base pairs, preferably greater than 15 bases or basepairs, more preferably greater than 20 bases or base pairs in length.

In general, dsRNA exerts an immunostimulatory effect and is encompassed by the invention. Further modifications of modified ISS include, but are not limited to, modifications of the 3'OH or 5'OH group, modifications of the nucleotide base, 15 modifications of the sugar component, and modifications of the phosphate group. Various such modifications are described below.

Modified Bases and Base Analogs

Oligonucleotides are polymers of nucleosides joined, generally, through 20 phosphoester linkages. A nucleoside consists of a purine (adenine or guanine or derivative thereof) or pyrimidine (thymine, cytosine or uracil, or derivative thereof) base bonded to a sugar. The four nucleoside units (or bases) in DNA are called deoxyadenosine, deoxyguanosine, deoxythymidine, and deoxycytidine. A nucleotide is a phosphate ester of a nucleoside.

25 Multiple bases, sugars, or phosphates in any combination can be substituted in the modified ISS.

The oligonucleotide of the invention can comprise ribonucleotides (containing ribose as the only or principal sugar component), deoxyribonucleotides (containing deoxyribose as the principal sugar component), or, in accordance with the state of the art, 30 modified sugars or sugar analogs can be incorporated in the modified ISS. Thus, in addition to ribose and deoxyribose, the sugar moiety can be pentose, deoxypentose, hexose, deoxyhexose, glucose, arabinose, xylose, lyxose, and a sugar "analog" cyclopentyl group.

The sugar can be in pyranosyl or in a furanosyl form. In the modified ISS, the sugar moiety is preferably the furanoside of ribose, deoxyribose, arabinose or 2'-O-methylribose, and the sugar can be attached to the respective heterocyclic bases either in α or β anomeric configuration. The preparation of these sugars or sugar analogs and the respective
5 "nucleosides" wherein such sugars or analogs are attached to a heterocyclic base (nucleic acid base) *per se* is known, and need not be described here, except to the extent such preparation can pertain to any specific example.

The phosphorous derivative (or modified phosphate group) which can be attached to the sugar or sugar analog moiety in the oligonucleotides of the present invention can be a
10 monophosphate, diphosphate, triphosphate, alkylphosphate, alkanephosphate, phosphorothioate, phosphorodithioate or the like. A phosphorothiate linkage can be used in place of a phosphodiester linkage. The preparation of the above-noted phosphate analogs, and their incorporation into nucleotides, modified nucleotides and oligonucleotides, *per se*, is also known and need not be described here in detail. Peyrottes et al. (1996) *Nucleic*
15 *Acids Res.* 24:1841-1848; Chaturvedi et al. (1996) *Nucleic Acids Res.* 24:2318-2323; and Schultz et al. (1996) *Nucleic Acids Res.* 24:2966-2973. Preferably, oligonucleotides of the present invention comprise phosphorothioate linkages. Oligonucleotides with phosphorothioate backbones can be more immunogenic than those with phosphodiester backbones and appear to be more resistant to degradation after injection into the host.
20 Braun et al. (1988) *J. Immunol.* 141:2084-2089; and Latimer et al. (1995) *Mol. Immunol.* 32:1057-1064.

The heterocyclic bases, or nucleic acid bases, which are incorporated in the modified ISS can be the naturally-occurring principal purine and pyrimidine bases, (namely uracil or thymine, cytosine, adenine and guanine, as mentioned above), as well as naturally-
25 occurring and synthetic modifications of said principal bases.

Those skilled in the art will recognize that a large number of "synthetic" non-natural nucleosides comprising various heterocyclic bases and various sugar moieties (and sugar analogs) are available in the art, and that as long as other criteria of the present invention are satisfied, the modified ISS can include one or several heterocyclic bases other
30 than the principal five base components of naturally-occurring nucleic acids. Preferably, however, the heterocyclic base in the modified ISS includes, but is not limited to, uracil-5-yl, cytosin-5-yl, adenin-7-yl, adenin-8-yl, guanin-7-yl, guanin-8-yl,

4-aminopyrrolo [2,3-d] pyrimidin-5-yl, 2-amino-4-oxopyrrolo [2,3-d] pyrimidin-5-yl, 2-amino-4-oxopyrrolo [2,3-d] pyrimidin-3-yl groups, where the purines are attached to the sugar moiety of the modified ISS via the 9-position, the pyrimidines via the 1-position, the pyrrolopyrimidines via the 7-position and the pyrazolopyrimidines via the 1-position.

5 A cytosine in the modified ISS can be substituted with a modified cytosine including, but not limited to, azacytosine, 5-bromocytosine, bromouracil, 5-chlorocytosine, chlorinated cytosine, cyclocytosine, cytosine arabinoside, fluorinated cytosine, fluoropyrimidine, fluorouracil, 5,6-dihydrocytosine, halogenated cytosine, halogenated pyrimidine analogue, hydroxyurea, iodouracil, 5-nitrocytosine, 5-trifluoromethyl-cytosine, 10 5,6-dihydrocytosine, uracil, and any other pyrimidine analog or modified pyrimidine. The present invention also includes dihydrocytosine analogs as potential potent activators of an immune response.

Methods of modulating immune responses with modified ISS

15 In one embodiment, the invention provides compositions comprising modified ISS as the only immunologically active substance. Upon administration, such modified ISS induces a stimulation of the immune system.

 In other embodiments, modified ISS can be administered in conjunction with one or more members of the group of immunomodulatory molecules comprising antigens 20 (including, but not limited to, proteins, glycoproteins, polysaccharides, and lipids), and/or immunomodulatory facilitators such as co-stimulatory molecules (including, but not limited to, cytokines, chemokines, targeting protein ligand, trans-activating factors, peptides, and peptides comprising a modified amino acid) and adjuvants (including, but not limited to, alum, lipid emulsions, and polylactide/polyglycolide microparticles). The term 25 "immunomodulatory" as used herein includes immunostimulatory as well as immunosuppressive effects. Immunostimulatory effects include, but are not limited to, those that directly or indirectly enhance cellular or humoral immune responses. Examples of immunostimulatory effects include, but are not limited to, increased antigen-specific antibody production; activation or proliferation of a lymphocyte population such as NK 30 cells, CD4⁺ T lymphocytes, CD8⁺ T lymphocytes, macrophages and the like; increased synthesis of immunostimulatory cytokines including, but not limited to, IL-1, IL-2, IL-4, IL-5, IL-6, IL-12, IFN- γ , TNF- α and the like. Immunosuppressive effects include those

that directly or indirectly decrease cellular or humoral immune responses. Examples of immunosuppressive effects include, but are not limited to, a reduction in antigen-specific antibody production such as reduced IgE production; activation of lymphocyte or other cell populations that have immunosuppressive activities such as those that result in immune tolerance; and increased synthesis of cytokines that have suppressive effects toward certain cellular functions. One example of this is IFN- γ , which appears to block IL-4 induced class switch to IgE and IgG1, thereby reducing the levels of these antibody subclasses.

The modified ISS and the antigen and/or immunomodulatory facilitator can be administered together in the form of a conjugate or co-administered in an admixture sufficiently close in time so as to modulate an immune response. Preferably, the modified ISS and immunomodulatory molecule are administered simultaneously. The term "co-administration" as used herein refers to the administration of at least two different substances sufficiently close in time to modulate an immune response. Preferably, co-administration refers to simultaneous administration of at least two different substances.

As used herein, the term "conjugate" refers to a complex in which a modified ISS and an immunomodulatory molecule are linked. Such conjugate linkages include covalent and/or non-covalent linkages.

As used herein, the term "antigen" means a substance that is recognized and bound specifically by an antibody or by a T cell antigen receptor. Antigens can include peptides, proteins, glycoproteins, polysaccharides, gangliosides and lipids; portions thereof and combinations thereof. The antigens can be those found in nature or can be synthetic. Haptens are included within the scope of "antigen." A hapten is a low molecular weight compound that is not immunogenic by itself but is rendered immunogenic when conjugated with an immunogenic molecule containing antigenic determinants.

As used herein, the term "adjuvant" refers to a substance which, when added to an immunogenic agent, nonspecifically enhances or potentiates an immune response to the agent in the recipient host upon exposure to the mixture.

In another embodiment, the invention provides compositions comprising modified ISS and an antigen. Antigens suitable for administration with modified ISS include any molecule capable of eliciting a B cell or T cell antigen-specific response. Preferably, antigens elicit an antibody response specific for the antigen. A wide variety of molecules are antigens. These include, but are not limited to, sugars, lipids and polypeptides, as well

as macromolecules such as complex carbohydrates, and phospholipids. Small molecules may need to be haptenized in order to be rendered antigenic. Preferably, antigens of the present invention include peptides, lipids (e.g. sterols, fatty acids, and phospholipids), polysaccharides such as those used in *Hemophilus influenza* vaccines, gangliosides and glycoproteins.

As used herein, the term "peptide" includes peptides and proteins that are of sufficient length and composition to effect a biological response, e.g. antibody production or cytokine activity whether or not the peptide is a hapten. Typically, the peptides are of at least six amino acid residues in length. The term "peptide" further includes modified amino acids, such modifications including, but not limited to, phosphorylation, glycosylation, pegylation, lipidization and methylation.

In one embodiment, the invention provides compositions comprising modified ISS and antigenic peptides. Antigenic peptides can include purified native peptides, synthetic peptides, recombinant proteins, crude protein extracts, attenuated or inactivated viruses, cells, micro-organisms, or fragments of such peptides.

Many antigenic peptides and proteins are known, and available in the art; others can be identified using conventional techniques. Protein antigens that can serve as immunomodulatory facilitators include, but are not limited to, the following examples. Isolated native or recombinant antigens can be derived from plant pollens (see, for example, Rafnar et al. (1991) *J. Biol. Chem.* 266:1229-1236; Breiteneder et al. (1989) *EMBO J.* 8:1935-1938; Elsayed et al. (1991) *Scand. J. Clin. Lab. Invest. Suppl.* 204:17-31; and Malley (1989) *J. Reprod. Immunol.* 16:173-186), dust mite proteins (see, for example, Chua et al. (1988) *J. Exp. Med.* 167:175-182; Chua et al. (1990) *Int. Arch. Allergy Appl. Immunol.* 91:124-129; and Joost van Neerven et al. (1993) *J. Immunol.* 151:2326-2335), animal dander (see, for example, Rogers et al. (1993) *Mol. Immunol.* 30:559-568), animal saliva, bee venom, and fungal spores. Live, attenuated and inactivated microorganisms such as HIV-1, HIV-2, herpes simplex virus, hepatitis A virus (Bradley et al. (1984) *J. Med. Virol.* 14:373-386), rotavirus, polio virus (Jiang et al. (1986) *J. Biol. Stand.* 14:103-109), hepatitis B virus, measles virus (James et al. (1995) *N. Engl. J. Med.* 332:1262-1266), human and bovine papilloma virus, and slow brain viruses can provide peptide antigens. For immunization against tumor formation, immunomodulatory peptides can include tumor cells (live or irradiated), tumor cell extracts, or protein subunits of tumor antigens.

Vaccines for immuno-based contraception can be formed by including sperm proteins administered with modified ISS. Lea et al. (1996) *Biochim. Biophys. Acta* 1307:263.

The modified ISS and antigen can be administered as a modified ISS-antigen conjugate and/or they can be co-administered as a complex in the form of an admixture, such as in an emulsion. The association of the modified ISS and the antigen molecules in a modified ISS-antigen conjugate can be through covalent interactions and/or through non-covalent interactions, including high affinity and/or low affinity interactions. Examples of non-covalent interactions that can couple a modified ISS and an antigen in a modified ISS-antigen conjugate include, but are not limited to, ionic bonds, hydrophobic interactions, hydrogen bonds and van der Waals attractions.

In another embodiment, modified ISS can be administered in conjunction with one or more immunomodulatory facilitator. Thus, the invention provides compositions comprising modified ISS and an immunomodulatory facilitator. As used herein, the term "immunomodulatory facilitator" refers to molecules which support and/or enhance the immunomodulatory activity of a modified ISS. Examples of immunomodulatory facilitators can include co-stimulatory molecules, such as cytokines, and/or adjuvants. The modified ISS and facilitator can be administered as a modified ISS-facilitator conjugate and/or they can be co-administered as a complex in the form of an admixture, such as in an emulsion. The association of the modified ISS and the facilitator molecules in a modified ISS-facilitator conjugate can be through covalent interactions and/or through non-covalent interactions, including high affinity and/or low affinity interactions. Examples of non-covalent interactions that can couple a modified ISS and a facilitator in a modified ISS-facilitator conjugate include, but are not limited to, ionic bonds, hydrophobic interactions, hydrogen bonds and van der Waals attractions.

Immunomodulatory facilitators include, but are not limited to, co-stimulatory molecules (such as cytokines, chemokines, targeting protein ligand, trans-activating factors, peptides, and peptides comprising a modified amino acid) and adjuvants (such as alum, lipid emulsions, and polylactide/polyglycolide microparticles).

Among suitable immunomodulatory cytokine peptides for administration with modified ISS are the interleukins (e.g., IL-1, IL-2, IL-3, etc.), interferons (e.g., IFN- α , IFN- β , IFN- γ), erythropoietin, colony stimulating factors (e.g., G-CSF, M-CSF, GM-CSF) and

TNF- α . Preferably, immunostimulatory peptides for use in conjunction with modified ISS oligonucleotides are those that stimulate Th1-type immune responses, such as IL-12 (Bliss et al. (1996) *J. Immunol.* 156:887-894), IL-18, TNF- α , β and γ , and/or transforming growth factor (TGF)- α .

5 Peptides administered with modified ISS can also include amino acid sequences that mediate protein binding to a specific receptor or that mediate targeting to a specific cell type or tissue. Examples include, but are not limited to, antibodies or antibody fragments, peptide hormones such as human growth hormone, and enzymes. Immunomodulatory peptides also include peptide hormones, peptide neurotransmitters and peptide growth
10 factors. Co-stimulatory molecules such as B7 (CD80), trans-activating proteins such as transcription factors, chemokines such as macrophage chemotactic protein (MCP) and other chemoattractant or chemotactic peptides are also useful peptides for administration with modified ISS.

 The modified ISS can also be conjugated to other antigens such as lipids,
15 polysaccharides, gangliosides and the like, through a linking group such as a peptide.

 The invention also provides for the administration of modified ISS in conjunction with an adjuvant. Administration of an antigen with a modified ISS and an adjuvant leads to a potentiation of a immune response to the antigen and thus, can result in an enhanced immune response compared to that which results from a composition comprising the
20 modified ISS and antigen alone. Thus, in another embodiment, the invention provides compositions comprising ISS, an antigen and an adjuvant whereby the modified ISS/antigen/adjuvant are co-administered. Preferably, the immunogenic composition contains an amount of an adjuvant sufficient to potentiate the immune response to the immunogen. Preferably, adjuvants include, but are not limited to, oil-in-water emulsions,
25 water-in oil emulsions, alum (aluminum salts), liposomes and microparticles, including but not limited to, polystyrene, starch, polyphosphazene and polylactide/polyglycosides. More preferably, the modified ISS and antigen are co-administered with alum. More preferably, the modified ISS and antigen are co-administered with liposomes. Still more preferably, the modified ISS and antigen are co-administered with an oil-in-water emulsion.

30 Suitable adjuvants also include, but are not limited to, squalene mixtures (SAF-1), muramyl peptide, saponin derivatives, mycobacterium cell wall preparations,

monophosphoryl lipid A, mycolic acid derivatives, nonionic block copolymer surfactants, Quil A, cholera toxin B subunit, polyphosphazene and derivatives, and immunostimulating complexes (ISCOMs) such as those described by Takahashi et al. (1990) *Nature* 344:873-875, as well as, lipid-based adjuvants and others described herein. For veterinary use and
5 for production of antibodies in animals, mitogenic components of Freund's adjuvant (both complete and incomplete) can be used.

As with all immunogenic compositions, the immunologically effective amounts of the components must be determined empirically. Factors to be considered include the antigenicity, whether or not modified ISS and/or antigen will be complexed with or
10 covalently attached to an immunomodulatory facilitator, an adjuvant or carrier protein or other carrier, route of administration and the number of immunizing doses to be administered. Such factors are known in the vaccine art and it is well within the skill of immunologists to make such determinations without undue experimentation.

The invention further provides for compositions in which modified ISS and an
15 immunomodulatory molecule(s) are in proximate association at a distance effective to enhance the immune response generated compared to the administration of the modified ISS and the immunomodulatory molecule as an admixture. Thus, the invention provides compositions and methods of use thereof comprising an encapsulating agent that can maintain the proximate association of the modified ISS and immunomodulatory molecule
20 until the complex is available to the target. Preferably, the composition comprising modified ISS, immunomodulatory molecule and encapsulating agent is in the form of adjuvant oil-in-water emulsions, microparticles and/or liposomes. More preferably, adjuvant oil-in-water emulsions, microparticles and/or liposomes encapsulating a modified ISS-immunomodulatory molecule are in the form of particles from about 0.04 μm to about
25 100 μm in size, more preferably, from about 0.1 μm to about 20 μm , even more preferably, from about 0.15 μm to about 10 μm .


Colloidal dispersion systems, such as microspheres, beads, macromolecular complexes, nanocapsules and lipid-based system, such as oil-in-water emulsions, micelles, mixed micelles and liposomes can provide effective encapsulation of modified ISS-
30 containing compositions.

The encapsulation composition further comprises any of a wide variety of components. These include, but are not limited to, alum, lipids, phospholipids, lipid membrane structures (LMS), polyethylene glycol (PEG) and other polymers, such as polypeptides, glycopeptides, and polysaccharides.

5 Polypeptides suitable for encapsulation components include any known in the art and include, but are not limited to, fatty acid binding proteins. Modified polypeptides contain any of a variety of modifications, including, but not limited to glycosylation, phosphorylation, myristylation, sulfation and hydroxylation. As used herein, a suitable polypeptide is one that will protect a modified ISS-containing composition to preserve the
10 immunomodulatory activity thereof. Examples of binding proteins include, but are not limited to, albumins such as bovine serum albumin (BSA) and pea albumin.

Other suitable polymers can be any known in the art of pharmaceuticals and include, but are not limited to, naturally-occurring polymers such as dextrans, hydroxyethyl starch, and polysaccharides, and synthetic polymers. Examples of naturally occurring
15 polymers include proteins, glycopeptides, polysaccharides, dextran and lipids. The additional polymer can be a synthetic polymer. Examples of synthetic polymers which are suitable for use in the present invention include, but are not limited to, polyalkyl glycols (PAG) such as PEG, polyoxyethylated polyols (POP), such as polyoxyethylated glycerol (POG), polytrimethylene glycol (PTG) polypropylene glycol (PPG), polyhydroxyethyl
20 methacrylate, polyvinyl alcohol (PVA), polyacrylic acid, polyethyloxazoline, polyacrylamide, polyvinylpyrrolidone (PVP), polyamino acids, polyurethane and polyphosphazene. The synthetic polymers can also be linear or branched, substituted or unsubstituted, homopolymeric, co-polymers, or block co-polymers of two or more different synthetic monomers.

25 PEGs constitute a diverse group of molecules. A general formula for PEGs is as follows:



where R_1 and R_3 are independently H, H_3C , OH, or a linear or branched, substituted
30 or unsubstituted alkyl group and n is an integer between 1 and about 1,000. The term "PEG" includes both unsubstituted (R_1 and $R_3 = H$) as well as substituted PEG. The PEGs

for use in encapsulation compositions of the present invention are either purchased from chemical suppliers or synthesized using techniques known to those of skill in the art.

The term "LMS", as used herein, means lamellar lipid particles wherein polar head groups of a polar lipid are arranged to face an aqueous phase of an interface to form membrane structures. Examples of the LMSs include liposomes, micelles, cochleates (i.e.,
5 generally cylindrical liposomes), microemulsions, unilamellar vesicles, multilamellar vesicles, and the like.

A preferred colloidal dispersion system of this invention is a liposome. In mice immunized with a liposome-encapsulated antigen, liposomes appeared to enhance a Th1-type immune response to the antigen. Aramaki et al. (1995) *Vaccine* 13:1809-1814. As
10 used herein, a "liposome" or "lipid vesicle" is a small vesicle bounded by at least one and possibly more than one bilayer lipid membrane. Liposomes are made artificially from phospholipids, glycolipids, lipids, steroids such as cholesterol, related molecules, or a combination thereof by any technique known in the art, including but not limited to
15 sonication, extrusion, or removal of detergent from lipid-detergent complexes. A liposome can also optionally comprise additional components, such as a tissue targeting component. It is understood that a "lipid membrane" or "lipid bilayer" need not consist exclusively of lipids, but can additionally contain any suitable other components, including, but not
20 limited to, cholesterol and other steroids, lipid-soluble chemicals, proteins of any length, and other amphipathic molecules, providing the general structure of the membrane is a sheet of two hydrophilic surfaces sandwiching a hydrophobic core. For a general discussion of membrane structure, see *The Encyclopedia of Molecular Biology* by J. Kendrew (1994). For suitable lipids see e.g., Lasic (1993) "Liposomes: from Physics to
Applications" Elsevier, Amsterdam.

25 Preferably, a liposomal composition is chosen that allows the membrane to be formed with reproducible qualities, such as diameter, and is stable in the presence of elements expected to occur where the liposome is to be used, such as physiological buffers and circulating molecules. Preferably, the liposome is resilient to the effects of manipulation by storage, freezing, and mixing with pharmaceutical excipients.

30 Lipids suitable for incorporation into lipid membrane structures include, but are not limited to, natural, semi-synthetic or synthetic mono- or di-glycerophospholipids including, but not limited to, phosphatidylcholines (PCs), phosphatidylethanolamines (PEs),

phosphatidylglycerols (PGs), phosphatidylinositols (PIs), phosphatidic acids (PAs), phosphatidylserines (PSs), glycerol- and cardiolipins. Sphingolipids such as sphingomyelin (SM) and cerebrosides can also be incorporated. While natural phospholipids occur with the phospho moiety at the *sn*-3 position and hydrophobic chains at the *sn*-1 and *sn*-2 positions, synthetic lipids can have alternative stereochemistry with, e.g., the phospho group at the *sn*-1 or *sn*-2 positions. Furthermore, the hydrophobic chains can be attached to the glycerol backbone by acyl, ether, alkyl or other linkages. Derivatives of these lipids are also suitable for incorporation into liposomes. Derivatives suitable for use include, but are not limited to, haloalkyl derivatives, including those in which all or some of the hydrogen atoms of the alkyl chains are substituted with, e.g., fluorine. In addition, cholesterol and other amphipathic steroids, bolaamphiphiles (lipids with polar moieties at either end of the molecule which form monolayer membranes) and polyglycerolmonoalkylthethers can also be incorporated. Liposomes can be composed of a single lipid or mixtures of two or more different lipids.

In one embodiment, the lipid bilayer of the liposome is formed primarily from phospholipids. Preferably, the phospholipid composition is a complex mixture, comprising a combination of PS and additional lipids such as PC, PA, PE, PG and SM, PI, and/or cardiolipin (diphosphatidylglycerol). If desired, SM can be replaced with a greater proportion of PC, PE, or a combination thereof. PS can be optionally replaced with PG. The composition is chosen so as to confer upon the LMS both stability during storage and administration.

Practitioners of ordinary skill will readily appreciate that each phospholipid in the foregoing list can vary in its structure depending on the fatty acid moieties that are esterified to the glycerol moiety of the phospholipid. Generally, most commercially available forms of a particular phospholipid can be used. However, phospholipids containing particular fatty acid moieties may be preferred for certain applications.

A general process for preparing liposomes containing modified ISS-containing compositions is as follows. An aqueous dispersion of liposomes is prepared from membrane components, such as phospholipids (e.g. PS, PC, PG, SM and PE) and glycolipids according to any known methods. See, e.g., *Ann. Rev. Biophys. Bioeng.* 9:467 (1980). The liposomes can further contain sterols, dialkylphosphates, diacylphosphatidic acids, stearylamine, α -tocopherol, etc., in the liposomal membrane.

To the liposomal dispersion thus prepared is added an aqueous solution of the modified ISS-containing composition and the mixture is allowed to stand for a given period of time, preferably under warming at a temperature above the phase transition temperature of the membrane or above 40°C, followed by cooling to thereby prepare liposomes
5 containing the modified ISS-containing composition in the liposomal membrane.

Alternatively, the desired liposomes can also be prepared by previously mixing the above-described membrane components and modified ISS-containing composition and treating the mixture in accordance with known methods for preparing liposomes.

The lipid vesicles can be prepared by any suitable technique known in the art.
10 Methods include, but are not limited to, microencapsulation, microfluidization, LLC method, ethanol injection, freon injection, the "bubble" method, detergent dialysis, hydration, sonication, and reverse-phase evaporation. Reviewed in Watwe et al. (1995) *Curr. Sci.* 68:715-724. For example, ultrasonication and dialysis methods generally produce small unilamellar vesicles; extrusion and reverse-phase evaporation generally
15 produce larger sized vesicles. Techniques may be combined in order to provide vesicles with the most desirable attributes.

Optionally, the LMS also includes steroids to improve the rigidity of the membrane. Any amount of a steroid can be used. Suitable steroids include, but are not limited to, cholesterol and cholestanol. Other molecules that can be used to increase the rigidity of the
20 membrane include, but are not limited to, cross-linked phospholipids.

Other preferred LMSs for use *in vivo* are those with an enhanced ability to evade the reticuloendothelial system, which normally phagocytoses and destroys non-native materials, thereby giving the liposomes a longer period in which to reach the target cell. Effective lipid compositions in this regard are those with a large proportion of SM and
25 cholesterol, or SM and PI. LMSs with prolonged circulation time also include those that comprise the monosialoganglioside GM1, glucuronide, or PEG.

The invention encompasses LMSs containing tissue or cellular targeting components. Such targeting components are components of a LMS that enhance its accumulation at certain tissue or cellular sites in preference to other tissue or cellular sites
30 when administered to an intact animal, organ, or cell culture. A targeting component is generally accessible from outside the liposome, and is therefore preferably either bound to the outer surface or inserted into the outer lipid bilayer. A targeting component can be

inter alia a peptide, a region of a larger peptide, an antibody specific for a cell surface molecule or marker, or antigen binding fragment thereof, a nucleic acid, a carbohydrate, a region of a complex carbohydrate, a special lipid, or a small molecule such as a drug, hormone, or hapten, attached to any of the aforementioned molecules. Antibodies with
5 specificity toward cell type-specific cell surface markers are known in the art and are readily prepared by methods known in the art.

The LMSs can be targeted to any cell type toward which a therapeutic treatment is to be directed, e.g., a cell type which can modulate and/or participate in an immune response. Such target cells and organs include, but are not limited to, APCs, such as
10 macrophages, dendritic cells and lymphocytes, lymphatic structures, such as lymph nodes and the spleen, and nonlymphatic structures, particularly those in which dendritic cells are found.

The LMS compositions of the present invention can additionally comprise surfactants. Surfactants can be cationic, anionic, amphiphilic, or nonionic. A preferred
15 class of surfactants are nonionic surfactants; particularly preferred are those that are water soluble. Nonionic, water soluble surfactants include polyoxyethylene derivatives of fatty alcohols, fatty acid ester of fatty alcohols and glyceryl esters, wherein the polyoxyethylene group is coupled via an ether linkage to an alcohol group. Examples include, but are not limited to, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene castor oil
20 derivatives, polyoxyethylene hardened castor oil derivatives, fatty acid sodium salts, sodium cholates, polyoxyethylene fatty acid ester and polyoxyethylene alkyl ethers.

The LMS compositions encompassed herein include micelles. The term "micelles" as used herein means aggregates which form from tenside molecules in aqueous solutions above a specific temperature (Krafft point) or a characteristic concentration, the critical
25 micellization concentration (cmc). When the cmc is exceeded, the monomer concentration remains practically constant and the excess tenside molecules form micelles. Micelles are thermodynamically stable association colloids of surfactant substances in which the hydrophobic radicals of the monomers lie in the interior of the aggregates and are held together by hydrophobic interaction; the hydrophilic groups face the water and by solvation
30 provide the solubility of the colloid. Micelles occur in various shapes (spheres, rods, discs) depending on the chemical constitution of the tenside and on the temperature, concentration

or ionic strength of the solution. Reaching the cmc is manifest by abrupt changes in surface tension, osmotic pressure, electrical conductivity and viscosity.

A process for preparing micelles containing modified ISS-containing compositions is as follows. A micelle-forming surfactant, such as polyoxyethylene sorbitan fatty acid esters, polyoxyethylene castor oil derivatives, polyoxyethylene hardened castor oil derivatives, fatty acid sodium salts, sodium cholates, polyoxyethylene fatty acid ester, and polyoxyethylene alkyl ethers, alkyl glycosides, is added to water at a concentration above the cmc to prepare a micellar dispersion. To the micellar dispersion is added an aqueous solution of a modified ISS-containing composition and the mixture is allowed to stand for a given period of time, preferably under warming at 40°C or higher, followed by cooling, to thereby prepare micelles containing modified ISS-containing compositions in the micellar membrane. Alternatively, the desired micelles can also be prepared by previously mixing the above-described micelle-forming substances and modified ISS-containing compositions and treating the mixture according to known methods for micelle formation.

Synthesis of the Modified ISS

a) Modified ISS

The modified ISS can be synthesized using techniques and nucleic acid synthesis equipment which are well known in the art including, but not limited to, enzymatic methods, chemical methods, and the degradation of larger oligonucleotide sequences. See, for example, Ausubel et al. (1987); and Sambrook et al. (1989). When assembled enzymatically, the individual units can be ligated, for example, with a ligase such as T4 DNA or RNA ligase. U.S. Patent No. 5,124,246. Chemical synthesis of oligonucleotides can involve conventional automated methods, such as the phosphoramidite method disclosed by Warner et al. (1984) *DNA* 3:401. See also U.S. Patent No. 4,458,066. Oligonucleotide degradation can be accomplished through the exposure of an oligonucleotide to a nuclease, as exemplified in U.S. Patent No. 4,650,675.

The modified ISS can also be isolated using conventional polynucleotide isolation procedures. Such procedures include, but are not limited to, hybridization of probes to genomic or cDNA libraries to detect shared nucleotide sequences, antibody screening of expression libraries to detect shared structural features and synthesis of particular native sequences by the polymerase chain reaction.

Circular modified ISS can be isolated, synthesized through recombinant methods, or chemically synthesized. Where the circular modified ISS is obtained through isolation or through recombinant methods, the modified ISS will preferably be a plasmid. The chemical synthesis of smaller circular oligonucleotides can be performed using any method described in the literature. See, for instance, Gao et al. (1995) *Nucleic Acids Res.* 23:2025-2029; and Wang et al. (1994) *Nucleic Acids Res.* 22:2326-2333.

The modified ISS can also contain phosphorous based modified oligonucleotides. These can be synthesized using standard chemical transformations. The efficient solid-support based construction of methylphosphonates has also been described. The synthesis of other phosphorous based modified oligonucleotides, such as phosphotriesters (Miller et al. (1971) *JACS* 93:6657-6665), phosphoramidates (Jager et al. (1988) *Biochem.* 27:7247-7246), and phosphorodithioates (U.S. Patent No. 5,453,496) has also been described. Other non-phosphorous based modified oligonucleotides can also be used. Stirchak et al. (1989) *Nucleic Acids Res.* 17:6129-6141.

The techniques for making phosphate group modifications to oligonucleotides are known in the art. For review of one such useful technique, an intermediate phosphate triester for the target oligonucleotide product is prepared and oxidized to the naturally occurring phosphate triester with aqueous iodine or with other agents, such as anhydrous amines. The resulting oligonucleotide phosphoramidates can be treated with sulfur to yield phosphorothioates. The same general technique (excepting the sulfur treatment step) can be applied to yield methylphosphoamidites from methylphosphonates. See also, U.S. Patent Nos. 4,425,732; 4,458,066; 5,218,103; and 5,453,496.

The preparation of base-modified nucleosides, and the synthesis of modified oligonucleotides using said base-modified nucleosides as precursors, has been described, for example, in U.S. Patents 4,910,300, 4,948,882, and 5,093,232. These base-modified nucleosides have been designed so that they can be incorporated by chemical synthesis into either terminal or internal positions of an oligonucleotide. Such base-modified nucleosides, present at either terminal or internal positions of an oligonucleotide, can serve as sites for attachment of a peptide or other antigen. Nucleosides modified in their sugar moiety have also been described (including, but not limited to, e.g., U.S. Patents 4,849,513, 5,015,733, 5,118,800, 5,118,802) and can be used similarly.

b) *Immunomodulatory Molecules*

Attenuated and inactivated viruses are suitable for use herein as the antigen. Preparation of these viruses is well-known in the art. Polio virus can be inactivated by chemical agents such as beta-propiolactone. Jiang et al. (1986). The growth of attenuated strains of Hepatitis A virus has been described (Bradley et al. (1984)), as well as the growth of attenuated measles virus (James et al. (1995)). Additionally, attenuated and inactivated viruses such as HIV-1, HIV-2, herpes simplex virus, hepatitis B virus, rotavirus, human and non-human papillomavirus and slow brain viruses can provide peptide antigens.

Allergens are suitable for use herein as immunomodulatory molecules. Preparation of many allergens is well-known in the art, including, but not limited to, preparation of ragweed pollen allergen Antigen E (*Amb al*) (Rafnar et al. 1991), major dust mite allergens *Der pI* and *Der pII* (Chua et al. (1988); and Chua et al. (1990)), white birch pollen *Betvl* (Breitneder et al. 1989), domestic cat allergen *Fel dI* (Rogers et al. (1993), and protein antigens from tree pollen (Elsayed et al. (1991)). Preparation of protein antigens from grass pollen for *in vivo* administration has been reported. Malley (1989).

Immunomodulatory peptides can be native or synthesized chemically or enzymatically. Any method of chemical synthesis known in the art is suitable. Solution phase peptide synthesis can be used to construct peptides of moderate size or, for the chemical construction of peptides, solid phase synthesis can be employed. Atherton et al. (1981) *Hoppe Seylers Z. Physiol. Chem.* 362:833-839. Proteolytic enzymes can also be utilized to couple amino acids to produce peptides. Kullmann (1987) *Enzymatic Peptide Synthesis*, CRC Press, Inc. Alternatively, the peptide can be obtained by using the biochemical machinery of a cell, or by isolation from a biological source. Recombinant DNA techniques can be employed for the production of peptides. Hames et al. (1987) *Transcription and Translation: A Practical Approach*, IRL Press. Peptides can also be isolated using standard techniques such as affinity chromatography.

Preferably the antigens are peptides, lipids (e.g. sterols, fatty acids, and phospholipids), polysaccharides such as those used in *H. influenza* vaccines, gangliosides and glycoproteins. These can be obtained through several methods known in the art, including isolation and synthesis using chemical and enzymatic methods. In certain cases, such as for many sterols, fatty acids and phospholipids, the antigenic portions of the molecules are commercially available.

c) *Modified ISS-Immunomodulatory Molecule Conjugates*

The modified ISS portion can be coupled with the immunomodulatory molecule portion of a conjugate in a variety of ways, including covalent and/or non-covalent interactions.

The link between the portions can be made at the 3' or 5' end of the modified ISS, or at a suitably modified base at an internal position in the modified ISS. If the immunomodulatory molecule is a peptide and contains a suitable reactive group (e.g., an N-hydroxysuccinimide ester) it can be reacted directly with the N⁴ amino group of cytosine residues. Depending on the number and location of cytosine residues in the modified ISS, specific labeling at one or more residues can be achieved.

Alternatively, modified oligonucleosides, such as are known in the art, can be incorporated at either terminus, or at internal positions in the modified ISS. These can contain blocked functional groups which, when deblocked, are reactive with a variety of functional groups which can be present on, or attached to, the immunomodulatory molecule of interest.

Where the immunomodulatory molecule is a peptide, this portion of the conjugate can be attached to the 3'-end of the modified ISS through solid support chemistry. For example, the modified ISS portion can be added to a polypeptide portion that has been pre-synthesized on a support. Haralambidis et al. (1990a) *Nucleic Acids Res.* 18:493-499; and Haralambidis et al. (1990b) *Nucleic Acids Res.* 18:501-505. Alternatively, the modified ISS can be synthesized such that it is connected to a solid support through a cleavable linker extending from the 3'-end. Upon chemical cleavage of the modified ISS from the support, a terminal thiol group is left at the 3'-end of the oligonucleotide (Zuckermann et al. (1987) *Nucleic Acids Res.* 15:5305-5321; and Corey et al. (1987) *Science* 238:1401-1403) or a terminal amine group is left at the 3'-end of the oligonucleotide (Nelson et al. (1989) *Nucleic Acids Res.* 17:1781-1794). Conjugation of the amino-modified modified ISS to amino groups of the peptide can be performed as described in Benoit et al. (1987) *Neuromethods* 6:43-72. Conjugation of the thiol-modified modified ISS to carboxyl groups of the peptide can be performed as described in Sinah et al. (1991) *Oligonucleotide Analogues: A Practical Approach*, IRL Press. Coupling of an oligonucleotide carrying an

appended maleimide to the thiol side chain of a cysteine residue of a peptide has also been described. Tung et al. (1991) *Bioconjug. Chem.* 2:464-465.

The peptide portion of the conjugate can be attached to the 5'-end of the modified ISS through an amine, thiol, or carboxyl group that has been incorporated into the
5 oligonucleotide during its synthesis. Preferably, while the oligonucleotide is fixed to the solid support, a linking group comprising a protected amine, thiol, or carboxyl at one end, and a phosphoramidite at the other, is covalently attached to the 5'-hydroxyl. Agrawal et al. (1986) *Nucleic Acids Res.* 14:6227-6245; Connolly (1985) *Nucleic Acids Res.* 13:4485-4502; Kremsky et al. (1987) *Nucleic Acids Res.* 15:2891-2909; Connolly (1987) *Nucleic*
10 *Acids Res.* 15:3131-3139; Bischoff et al. (1987) *Anal. Biochem.* 164:336-344; Blanks et al. (1988) *Nucleic Acids Res.* 16:10283-10299; and U.S. Patent Nos. 4,849,513, 5,015,733, 5,118,800, and 5,118,802. Subsequent to deprotection, the latent amine, thiol, and carboxyl functionalities can be used to covalently attach the oligonucleotide to a peptide. Benoit et al. (1987); and Sinah et al. (1991).

15 The peptide portion can be attached to a modified cytosine or uracil at any position in the modified ISS. The incorporation of a "linker arm" possessing a latent reactive functionality, such as an amine or carboxyl group, at C-5 of the modified base provides a handle for the peptide linkage. Ruth, *4th Annual Congress for Recombinant DNA Research*, p. 123.

20 A modified ISS-immunomodulatory molecule conjugate can also be formed through non-covalent interactions, such as ionic bonds, hydrophobic interactions, hydrogen bonds and/or van der Waals attractions.

Non-covalently linked conjugates can include a non-covalent interaction such as a biotin-streptavidin complex. A biotinyl group can be attached, for example, to a modified
25 base of an ISS. Roget et al. (1989) *Nucleic Acids Res.* 17:7643-7651. Incorporation of a streptavidin moiety into the peptide portion allows formation of a non-covalently bound complex of the streptavidin conjugated peptide and the biotinylated oligonucleotide.

Non-covalent associations can also occur through ionic interactions involving a modified ISS and residues within the immunomodulatory molecule, such as charged amino
30 acids, or through the use of a linker portion comprising charged residues that can interact with both the oligonucleotide and the immunomodulatory molecule. For example, non-covalent conjugation can occur between a generally negatively-charged modified ISS and

positively-charged amino acid residues of a peptide, e.g., polylysine and polyarginine residues.

Non-covalent conjugation between modified ISS and immunomodulatory molecules can occur through DNA binding motifs of molecules that interact with DNA as their natural
5 ligands. For example, such DNA binding motifs can be found in transcription factors and anti-DNA antibodies.

The linkage of the modified ISS to a lipid can be formed using standard methods. These methods include, but are not limited to, the synthesis of oligonucleotide-phospholipid conjugates (Yanagawa et al. (1988) *Nucleic Acids Symp. Ser.* 19:189-192),
10 oligonucleotide-fatty acid conjugates (Grabarek et al. (1990) *Anal. Biochem.* 185:131-135; and Staros et al. (1986) *Anal. Biochem.* 156:220-222), and oligonucleotide-sterol conjugates. Boujrad et al. (1993) *Proc. Natl. Acad. Sci. USA* 90:5728-5731.

The linkage of the oligonucleotide to an oligosaccharide can be formed using standard known methods. These methods include, but are not limited to, the synthesis of
15 oligonucleotide-oligosaccharide conjugates, wherein the oligosaccharide is a moiety of an immunoglobulin. O'Shannessy et al. (1985) *J. Applied Biochem.* 7:347-355.

The linkage of a circular modified ISS to a peptide or antigen can be formed in several ways. Where the circular modified ISS is synthesized using recombinant or chemical methods, a modified nucleoside is suitable. Ruth (1991) in *Oligonucleotides and
20 Analogues: A Practical Approach*, IRL Press. Standard linking technology can then be used to connect the circular modified ISS to the antigen or other peptide. Goodchild (1990) *Bioconjug. Chem.* 1:165. Where the circular modified ISS is isolated, or synthesized using recombinant or chemical methods, the linkage can be formed by chemically activating, or photoactivating, a reactive group (e.g. carbene, radical) that has been incorporated into the
25 antigen or other peptide.

Additional methods for the attachment of peptides and other molecules to oligonucleotides can be found in U.S. Patent No. 5,391,723; Kessler (1992) "Nonradioactive labeling methods for nucleic acids" in Kricka (ed.) *Nonisotopic DNA
Probe Techniques*, Academic Press; and Geoghegan et al. (1992) *Bioconjug. Chem.* 3:138-
30 146.

Assessment of immune response to modified ISS

Analysis (both qualitative and quantitative) of the immune response to modified ISS-containing compositions can be by any method known in the art, including, but not limited to, measuring antigen-specific antibody production, activation of specific populations of lymphocytes such as CD4⁺ T cells or NK cells, and/or production of cytokines such as IFN, IL-2, IL-4, or IL-12. Methods for measuring specific antibody responses include enzyme-linked immunosorbent assay (ELISA) and are well known in the art. Measurement of numbers of specific types of lymphocytes such as CD4⁺ T cells can be achieved, for example, with fluorescence-activated cell sorting (FACS). Cytotoxicity assays can be performed for instance as described in Raz et al. (1994) *Proc. Natl. Acad. Sci. USA* 91:9519-9523. Serum concentrations of cytokines can be measured, for example, by ELISA. These and other assays to evaluate the immune response to an immunogen are well known in the art. See, for example, *Selected Methods in Cellular Immunology* (1980) Mishell and Shiigi, eds., W.H. Freeman and Co.

15 Administration of the Modified ISS

The modified ISS can be administered alone or in combination with other pharmaceutical and/or immunogenic and/or immunostimulatory agents and can be combined with a physiologically acceptable carrier thereof. The effective amount and method of administration of the particular modified ISS formulation can vary based on the individual patient and the stage of the disease and other factors evident to one skilled in the art. The route(s) of administration useful in a particular application are apparent to one of skill in the art. Routes of administration include but are not limited to topical, dermal, transdermal, transmucosal, epidermal parenteral, gastrointestinal, and naso-pharyngeal and pulmonary, including transbronchial and transalveolar. A suitable dosage range is one that provides sufficient modified ISS-containing composition to attain a tissue concentration of about 1-10 μ M as measured by blood levels. The absolute amount given to each patient depends on pharmacological properties such as bioavailability, clearance rate and route of administration.

As described herein, APCs and tissues with high concentration of APCs are preferred targets for the modified ISS-containing compositions. Thus, administration of modified ISS to mammalian skin and/or mucosa, where APCs are present in relatively high concentration, is preferred.

The present invention provides modified ISS-containing compositions suitable for topical application including, but not limited to, physiologically acceptable implants, ointments, creams, rinses and gels. Topical administration is, for instance, by a dressing or bandage having dispersed therein a delivery system, or by direct administration of a delivery system into incisions or open wounds. Creams, rinses, gels or ointments having dispersed therein a modified ISS-containing composition are suitable for use as topical ointments or wound filling agents.

Preferred routes of dermal administration are those which are least invasive. Preferred among these means are transdermal transmission, epidermal administration and subcutaneous injection. Of these means, epidermal administration is preferred for the greater concentrations of APCs expected to be in intradermal tissue.

Transdermal administration is accomplished by application of a cream, rinse, gel, etc. capable of allowing the modified ISS-containing composition to penetrate the skin and enter the blood stream. Compositions suitable for transdermal administration include, but are not limited to, pharmaceutically acceptable suspensions, oils, creams and ointments applied directly to the skin or incorporated into a protective carrier such as a transdermal device (so-called "patch"). Examples of suitable creams, ointments etc. can be found, for instance, in the Physician's Desk Reference.

For transdermal transmission, iontophoresis is a suitable method. Iontophoretic transmission can be accomplished using commercially available patches which deliver their product continuously through unbroken skin for periods of several days or more. Use of this method allows for controlled transmission of pharmaceutical compositions in relatively great concentrations, permits infusion of combination drugs and allows for contemporaneous use of an absorption promoter.

An exemplary patch product for use in this method is the LECTRO PATCH trademarked product of General Medical Company of Los Angeles, CA. This product electronically maintains reservoir electrodes at neutral pH and can be adapted to provide dosages of differing concentrations, to dose continuously and/or periodically. Preparation and use of the patch should be performed according to the manufacturer's printed instructions which accompany the LECTRO PATCH product; those instructions are incorporated herein by this reference.

For transdermal transmission, low-frequency ultrasonic delivery is also a suitable method. Mitragotri et al. (1995) *Science* 269:850-853. Application of low-frequency ultrasonic frequencies (about 1 MHz) allows the general controlled delivery of therapeutic compositions, including those of high molecular weight.

5 Epidermal administration essentially involves mechanically or chemically irritating the outermost layer of the epidermis sufficiently to provoke an immune response to the irritant. Specifically, the irritation should be sufficient to attract APCs to the site of irritation.

10 An exemplary mechanical irritant means employs a multiplicity of very narrow diameter, short tines which can be used to irritate the skin and attract APCs to the site of irritation, to take up modified ISS-containing compositions transferred from the end of the tines. For example, the MONO-VACC old tuberculin test manufactured by Pasteur Merieux of Lyon, France contains a device suitable for introduction of modified ISS-containing compositions.

15 The device (which is distributed in the U.S. by Connaught Laboratories, Inc. of Swiftwater, PA) consists of a plastic container having a syringe plunger at one end and a tine disk at the other. The tine disk supports a multiplicity of narrow diameter tines of a length which will just scratch the outermost layer of epidermal cells. Each of the tines in the MONO-VACC kit is coated with old tuberculin; in the present invention, each needle is
20 coated with a pharmaceutical composition of modified ISS-containing composition. Use of the device is preferably according to the manufacturer's written instructions included with the device product. Similar devices which can also be used in this embodiment are those which are currently used to perform allergy tests.

25 Another suitable approach to epidermal administration of modified ISS is by use of a chemical which irritates the outermost cells of the epidermis, thus provoking a sufficient immune response to attract APCs to the area. An example is a keratinolytic agent, such as the salicylic acid used in the commercially available topical depilatory creme sold by Noxema Corporation under the trademark NAIR. This approach can also be used to achieve epithelial administration in the mucosa. The chemical irritant can also be applied
30 in conjunction with the mechanical irritant (as, for example, would occur if the MONO-VACC type tine were also coated with the chemical irritant). The modified ISS can be

suspended in a carrier which also contains the chemical irritant or coadministered therewith.

Another delivery method for administering modified ISS-containing compositions makes use of non-lipid polymers, such as a synthetic polycationic amino polymer. Leff
5 (1997) *Bioworld* 86:1-2.

Parenteral routes of administration include but are not limited to electrical (iontophoresis) or direct injection such as direct injection into a central venous line, intravenous, intramuscular, intraperitoneal, intradermal, or subcutaneous injection. Compositions suitable for parenteral administration include, but are not limited, to
10 pharmaceutically acceptable sterile isotonic solutions. Such solutions include, but are not limited to, saline and phosphate buffered saline for injection of the modified ISS-containing compositions.

Gastrointestinal routes of administration include, but are not limited to, ingestion and rectal. The invention includes modified ISS-containing compositions suitable for
15 gastrointestinal administration including, but not limited to, pharmaceutically acceptable, powders, pills or liquids for ingestion and suppositories for rectal administration.

Naso-pharyngeal and pulmonary routes of administration include, but are not limited to, by-inhalation, transbronchial and transalveolar routes. The invention includes ISS-containing compositions suitable for by-inhalation administration including, but not
20 limited to, various types of aerosols for inhalation, as well as powder forms for delivery systems. Devices suitable for by-inhalation administration of modified ISS-containing compositions include, but are not limited to, atomizers and vaporizers. Atomizers and vaporizers filled with the powders are among a variety of devices suitable for use in by-inhalation delivery of powders. See, e.g., Lindberg (1993) Summary of Lecture at
25 Management Forum 6-7 December 1993 "Creating the Future for Portable Inhalers."

The methods of producing suitable devices for injection, topical application, atomizers and vaporizers are known in the art and will not be described in detail.

The choice of delivery routes can be used to modulate the immune response elicited. For example, IgG titers and CTL activities were identical when an influenza virus
30 vector was administered via intramuscular or epidermal (gene gun) routes; however, the muscular inoculation yielded primarily IgG2A, while the epidermal route yielded mostly IgG1. Pertmer et al. (1996) *J. Virol.* 70:6119-6125. Thus, one of skill in the art can take

advantage of slight differences in immunogenicity elicited by different routes of administering the immunomodulatory oligonucleotides of the present invention.

The above-mentioned compositions and methods of administration are meant to describe but not limit the methods of administering the modified ISS-containing compositions of the invention. The methods of producing the various compositions and devices are within the ability of one skilled in the art and are not described in detail here.

The following examples are provided to illustrate but not limit the invention.

EXAMPLES

EXAMPLE 1

Stimulation of cytokine production by oligonucleotides comprising modified ISS

Several oligonucleotides comprising modified ISS were tested for their immunostimulatory activity on mouse splenocytes and on human peripheral blood mononuclear cells (hPBMCs). Immunostimulation in response to oligonucleotide was assessed by measurement of cytokine secretion into the culture media and by cell proliferation. Cytokine levels in the culture supernatant were determined by enzyme-linked immunosorbent assay (ELISA) tests.

The oligonucleotides were synthesized using standard solid phase oligonucleotide techniques. The solid phase ready analog monomers were purchased from Glen Research, Sterling, VA and included in the standard manner in a solid phase oligonucleotide synthesizer. The synthesis of the oligonucleotides were performed by TriLink BioTechnologies Inc., San Diego, CA.

Cells were isolated and prepared using standard techniques. hPBMCs were isolated from heparinized peripheral blood from healthy donors by ficoll Hypaque gradients. Splens of BALB/c mice were harvested and the splenocytes isolated using standard teasing and treatment with ACK lysing buffer from BioWhittaker, Inc. Isolated cells were washed in RPMI 1640 media supplemented with 2% heat-inactivated fetal calf serum (FCS), 50 μ M 2-mercaptoethanol, 1% penicillin-streptomycin, and 2 mM L-glutamine and resuspended at approximately 4×10^6 cells/ml in 10%FCS/RPMI (RPMI 1640 media with 10% heat-inactivated FCS, 50 μ M 2-mercaptoethanol, 1% penicillin-streptomycin, and 2 mM L-glutamine).

Generally, cell cultures were set up in triplicate with approximately 4×10^5 cells/well in a 96-well, flat microtiter plate in 100 μ l 10%FCS/RPMI with the cells allowed to rest for at least 1 hour after plating. For oligonucleotide activity assays, oligonucleotides were diluted in 10%FCS/RPMI and 100 μ l of the desired oligonucleotide dilution was added to the appropriate well. In general, final oligonucleotide concentrations included 0.1 μ g/ml, 1.0 μ g/ml, and 10 μ g/ml. Cells were then incubated for 1, 2, or 3 days.

To determine cell proliferation, 100 μ l of supernatant was harvested from each well on appropriate days, pulsed with 1.0 μ M tritiated thymidine and incubated overnight. Standard methods to assess tritiated thymidine incorporation were used to determine cell proliferation. Cytokine production by the cells was determined by ELISAs of culture supernatant using commercially-available antibodies to the cytokines. Examples of results of such experiments are graphically depicted in Figures 2-4. The oligonucleotides used included the following:

Table 1

SEQ ID NO:	Oligonucleotide Sequence	
1	tgactgtg <u>aacgttcg</u> agatga	ISS (bold, underline)
2	tgactgtg <u>aabgttcc</u> agatga	b = 5-bromocytosine
3	tgactgtgaagcttagagatga	no ISS
4	tcactctcttccttactcttct	no ISS
5	tgactgtg <u>aabgttcg</u> agatga	b = 5-bromocytosine
6	tgactgtg <u>aabgttbq</u> agatga	b = 5-bromocytosine
7	tccat <u>gabgttcg</u> tgatcgt	b = 5-bromocytosine
8	tccat <u>aabgttcct</u> gatgct	b = 5-bromocytosine
9	tccat <u>aabgttcg</u> tgatgct	b = 5-bromocytosine
10	tccat <u>aabgttcg</u> cct <u>aacgttcg</u>	b = 5-bromocytosine
11	tccat <u>aabgttcg</u> cct <u>aabgttcg</u>	b = 5-bromocytosine

Results from an experiment in which mouse splenocytes were treated with 10 μ g/ml or 1 μ g/ml of the oligonucleotides listed in Table 1 are depicted in Figures 2-4. Treatment of the cells with oligonucleotides comprising at least one ISS resulted in the production of IL-6 and IL-12 from the cells, as well as a stimulation of cell proliferation. See, for example, Figs. 2-4, oligonucleotide 1. The oligonucleotides comprising a modified ISS

were, in general, as effective as or more effective than the oligonucleotide with an unmodified ISS. See, for example, Figs. 2-4, oligonucleotides 2, 5-11. Oligonucleotides without an ISS were unable to stimulate IL-6 or IL-12 production or cell proliferation. See, for example, Figs. 2-4, oligonucleotides 3 and 4. All oligonucleotides used in this experiment contained a phosphorothioate backbone.

EXAMPLE 2

Potential of an immune response with adjuvant co-administration

The effect of adjuvant co-administration with antigen and modified ISS (mISS) on an immune response to the antigen is examined using the adjuvants alum and MF59. Compositions comprising 1 μ g AgE, a major allergic component is short ragweed, is injected intradermally into mice at week 0, 2, and 4. Antigen compositions usable are listed below:

AgE	AgE-mISS conjugate
AgE + mISS mix (equivalent)	AgE + mISS mix (50 μ g mISS)
AgE and MF59	AgE-mISS conjugate and MF59
AgE and alum (25 μ g)	AgE-mISS conjugate and alum (25 μ g)
AgE and alum (800 μ g)	

The amount of anti-AgE antibody in the serum of the mice is determined at day 0 and weeks 2, 4, and 6. Anti-AgE antibody assays (IgE, IgG1, IgG2a) are performed by ELISA tests using the original AgE vaccine as the coated antigen on microtiter plates as described in Raz et al. (1996).

A comparison of anti-AgE antibody production, including anti-AgE antibody subtypes, provides an indication as to the level and type of immune response that results from each administered composition.

EXAMPLE 3

Selective Induction of a Th1-type Response in a Host after Administration of a Composition Comprising a modified ISS

In mice, IgG2A antibodies are serological markers for a Th1-type immune
5 response, whereas IgG1 antibodies are indicative of a Th2-type immune response. The production of the cytokine IFN- γ is also an indicator of a Th1-type response.

To determine which response, if any, would be produced by mice who received modified ISS compositions according to the invention, groups of BALB/c mice are immunized with 10 μ g β -galactosidase (β -Gal) protein. Some mice receive β -Gal alone,
10 some receive a modified ISS- β -Gal conjugate, some receive a modified ISS- β -Gal-adjuvant composition, and some receive a composition of β -Gal with a nonstimulatory oligonucleotide. Naïve mice are also included in the experiment.

At two week intervals, any IgG2A and IgG1 to β -Gal present in the serum of each mouse is measured by ELISA on microtiter plates coated with β -Gal. The titers of anti- β -
15 Gal IgG2A and IgG1 antibodies from mice are compared to determine whether the immune response, if any, is of the Th1- or Th2-type.

Another set of BALB/c mice are immunized with β -Gal as described above and sacrificed 24 hours later. Spleens are harvested from each mouse and splenocytes are isolated as described previously. The splenocytes are added to microtiter wells pre-coated
20 with anti-CD-3 antibody. (The anti-CD-3 antibody stimulates T cells through the T cell receptor complex.) The splenocytes are cultured in RPMI 1640 with 10% FBS at 4×10^5 cells/well and the supernatants sampled at 24, 48, and 72 hours of culture. Cytokine production by the splenocytes is determined with ELISA tests as described above. Relatively high levels of IFN- γ and IL-12 and relatively low levels of IL-4 would be
25 expected with a Th1-type immune response. Relatively low levels of IFN- γ and IL-12 and relatively high levels of IL-4 would be expected with a Th2-type immune response. CTL activity of the splenocytes is determined.

Although the foregoing invention has been described in some detail by way of
30 illustration and example for purposes of clarity of understanding, it will be apparent to those skilled in the art that certain changes and modifications may be practiced. Therefore,

the descriptions and examples should not be construed as limiting the scope of the invention, which is delineated by the appended claims.

CLAIMS

We claim:

1. An immunomodulatory oligonucleotide comprising an immunostimulatory sequence (ISS) comprising a modified cytosine.

5

2. An immunomodulatory oligonucleotide of claim 1, wherein the modified cytosine comprises an addition of an electron-withdrawing group to at least position C-5.

10

3. An immunomodulatory oligonucleotide of claim 1, wherein the modified cytosine comprises an addition of an electron-withdrawing group to at least position C-6.

15

4. An immunomodulatory oligonucleotide of claim 1, wherein the ISS comprises a modified cytosine selected from the group consisting of azacytosine, 5-bromocytosine, bromouracil, 5-chlorocytosine, chlorinated cytosine, cyclocytosine, cytosine arabinoside, fluorinated cytosine, fluoropyrimidine, fluorouracil, 5,6-dihydrocytosine, halogenated cytosine, halogenated pyrimidine analogue, hydroxyurea, iodouracil, 5-nitrocytosine, 5-trifluoromethyl-cytosine, uracil, 5-fluorocytosine, 5-trifluoromethylcytosine, and 5,6-dihydrocytosine.

20

5. An immunomodulatory oligonucleotide of claim 1, wherein the modified cytosine is a 5'-bromocytidine.

25

6. An immunomodulatory oligonucleotide of claim 1, wherein the ISS comprises the sequence 5'-Purine, Purine, Cytosine, Guanine, Pyrimidine, Pyrimidine-3'.

30

7. An immunomodulatory oligonucleotide of claim 6, wherein the modified cytosine comprises an addition of an electron-withdrawing group to at least position C-5.

8. An immunomodulatory oligonucleotide of claim 6, wherein the modified cytosine comprises an addition of an electron-withdrawing group to at least position C-6.

5 9. An immunomodulatory oligonucleotide of claim 6, wherein the modified cytosine is a 5'-bromocytidine.

10 10. An immunomodulatory oligonucleotide of claim 9, wherein the cytosine at the third position from the 5' end of the ISS octanucleotide is substituted with a 5'-bromocytidine.

15 11. An immunomodulatory oligonucleotide of claim 1, wherein the ISS comprises the sequence 5'-Purine, Purine, Cytosine, Guanine, Pyrimidine, Pyrimidine, Cytosine, Cytosine-3'.

12. An immunomodulatory oligonucleotide of claim 11, wherein the modified cytosine comprises an addition of an electron-withdrawing group to at least position C-5.

20 13. An immunomodulatory oligonucleotide of claim 11, wherein the modified cytosine comprises an addition of an electron-withdrawing group to at least position C-6.

25 14. An immunomodulatory oligonucleotide of claim 11, wherein the modified cytosine is a 5'-bromocytidine.

30 15. An immunomodulatory oligonucleotide of claim 11, wherein the cytosine at the third position from the 5' end of the ISS is substituted with a 5'-bromocytidine.

16. An immunomodulatory oligonucleotide of claim 11, wherein the cytosine at the third position from the 5' end of the ISS is substituted with a 5'-bromocytidine and the cytosine at the seventh position from the 5' end of the ISS is substituted with a 5'-bromocytidine.

5

17. An immunomodulatory oligonucleotide of claim 1, wherein the ISS comprises the sequence 5'-Purine, Purine, Cytosine, Guanine, Pyrimidine, Pyrimidine, Cytosine, Guanine-3'.

10

18. An immunomodulatory oligonucleotide of claim 17, wherein the modified cytosine comprises an addition of an electron-withdrawing group to at least position C-5.

15

19. An immunomodulatory oligonucleotide of claim 17, wherein the modified cytosine comprises an addition of an electron-withdrawing group to at least position C-6.

20

20. An immunomodulatory oligonucleotide of claim 17, wherein the modified cytosine is a 5'-bromocytidine.

25

21. An immunomodulatory oligonucleotide of claim 17, wherein the Cytosine at the third position from the 5' end of the ISS octanucleotide is substituted with a 5'-bromocytidine.

30

22. An immunomodulatory oligonucleotide of claim 17, wherein the cytosine at the third position from the 5' end of the ISS is substituted with a 5'-bromocytidine and the cytosine at the seventh position from the 5' end of the ISS is substituted with a 5'-bromocytidine.

23. An immunomodulatory oligonucleotide of claim 1, wherein the ISS comprises a phosphorothioate group.

24. An immunomodulatory oligonucleotide of claim 1, wherein the ISS comprises a sequence selected from the group consisting of AACGTT, GACGTT, AACGTTCC, AACGTTTCG, GACGTTCC, and GACGTTTCG, wherein at least one C is substituted with a modified cytosine.

5

25. An immunomodulatory oligonucleotide of claim 24, wherein the ISS further comprises a second modified cytosine.

10

26. An immunomodulatory oligonucleotide of claim 1, wherein the oligonucleotide portion further comprises an RNA sequence.

15

27. An immunomodulatory oligonucleotide of claim 26, wherein the ISS is an RNA sequence comprising a single-stranded or double-stranded sequence selected from the group consisting of AACGUU, GACGUU, AACGUUCC, AACGUUCG, GACGUUCC, and GACGUUCG, wherein at least one C is substituted with a modified cytosine.

20

28. An immunomodulatory oligonucleotide of claim 27, wherein the ISS further comprises a second modified cytosine.

25

29. An immunomodulatory oligonucleotide comprising the sequence SEQ ID NO:2.

30. An immunomodulatory oligonucleotide comprising the sequence SEQ ID NO:5.

31. An immunomodulatory oligonucleotide comprising the sequence SEQ ID NO:6.

30

32. An immunomodulatory composition comprising an immunomodulatory oligonucleotide according to claim 1;

and further comprising an antigen.

33. An immunomodulatory composition of claim 32, wherein the antigen is selected from the group consisting of peptides, glycoproteins, polysaccharides, and lipids.

34. An immunomodulatory composition of claim 32, wherein the antigen is conjugated to the immunomodulatory oligonucleotide.

35. An immunomodulatory composition comprising
an immunomodulatory oligonucleotide according to claim 1;
and further comprising a facilitator selected from the group consisting of co-stimulatory molecules, cytokines, chemokines, targeting protein ligand, a trans-activating factor, a peptide, and a peptide comprising a modified amino acid.

36. An immunomodulatory composition of claim 35, wherein the facilitator is conjugated to the immunomodulatory oligonucleotide.

37. An immunomodulatory composition comprising
an immunomodulatory oligonucleotide according to claim 1;
and further comprising an antigen;
and further comprising an adjuvant.

38. An immunomodulatory composition of claim 37, wherein the antigen is selected from the group consisting of peptides, glycoproteins, polysaccharides, and lipids.

39. An immunomodulatory composition of claim 37, wherein the antigen is conjugated to the immunomodulatory oligonucleotide.

40. A method of modulating an immune response comprising co-administration of an immunomodulatory composition comprising an antigen and an immunomodulatory oligonucleotide according to claim 1.

5 41. The method of claim 40, wherein the modulating of an immune response comprises induction of a Th1-type response.

42. A method of modulating an immune response comprising administration of an immunomodulatory composition according to claim 34.

10

43. The method of claim 42, wherein the modulating of an immune response comprises induction of a Th1-type response.

15 44. A method of modulating an immune response comprising the co-administration of an antigen, an adjuvant and an immunomodulatory oligonucleotide according to claim 1.

45. The method of claim 44, wherein the modulating of an immune response comprises induction of a Th1-type response.

20

46. A method of modulating an immune response comprising the administration of an immunomodulatory composition according to claim 35, wherein the components of the composition are co-administered.

25 47. A method of modulating an immune response comprising administration of an immunomodulatory composition according to claim 39.

30 48. A method of treating an individual in need of immune modulation comprising administration of a composition comprising an immunomodulatory oligonucleotide of claim 1.

1/4

R = H cytosine
R = CH₃ 5-methylcytosine
R = Br 5-bromocytosine




Fig. 1

2/4




Fig. 2

3/4




Fig. 3

4/4




Fig. 4

SEQUENCE LISTING

<110> Dynavax Technologies Corporation
Schwartz, David

<120> IMMUNOSTIMULATORY OLIGONUCLEOTIDES WITH
MODIFIED BASES AND METHODS OF USE THEREOF

<130> 377882000240

<140> Unassigned

<141> 1999-06-04

<150> 60/088,310

<151> 1998-06-05

<150> Unassigned

<151> 1999-06-01

<160> 11

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 22

<212> DNA

<213> Mus musculus

<400> 1

tgactgtgaa cgttcgagat ga

22

<210> 2

<211> 22

<212> DNA

<213> Mus musculus

<220>

<221> modified_base

<223> (11)...(11)

<223> 5-bromocytosine

<400> 2

tgactgtgaa ngttccagat ga

22

<210> 3

<211> 22

<212> DNA

<213> Mus musculus

<400> 3

tgactgtgaa gotttagagat ga

22

<210> 4

<211> 22

<212> DNA

<213> Mus musculus

<400> 4
tcactctctt ccttactctt ct 22

<210> 5
<211> 22
<212> DNA
<213> Mus musculus

<220>
<221> modified_base
<222> (11)...(11)
<223> 5-bromocytosine

<400> 5
tgactgtgaa ngttcgagat ga 22

<210> 6
<211> 22
<212> DNA
<213> Mus musculus

<220>
<221> modified_base
<222> (11)...(11)
<223> 5-bromocytosine

<221> modified_base
<222> (15)...(15)
<223> 5-bromocytosine

<400> 6
tgactgtgaa ngttngagat ga 22

<210> 7
<211> 20
<212> DNA
<213> Mus musculus

<220>
<221> modified_base
<222> (8)...(8)
<223> 5-bromocytosine

<400> 7
tccatgaggt tegtgatcgt 20

<210> 8
<211> 20
<212> DNA
<213> Mus musculus

<220>
<221> modified_base
<222> (8)...(8)
<223> 5-bromocytosine

<400> 8
tccataangt tcttgatgct 20

<210> 9
<211> 20
<212> DNA
<213> Mus musculus

<220>
<221> modified_base
<222> (8)...(8)
<223> 5-bromocytosine

<400> 9
tccataangt tcgtgatgct 20

<210> 10
<211> 24
<212> DNA
<213> Mus musculus

<220>
<221> modified_base
<222> (8)...(8)
<223> 5-bromocytosine

<400> 10
tccataangt tcgcctaacg ttcg 24

<210> 11
<211> 24
<212> DNA
<213> Mus musculus

<220>
<221> modified_base
<222> (8)...(8)
<223> 5-bromocytosine

<221> modified_base
<222> (19)...(19)
<223> 5-bromocytosine

<400> 11
tccataangt tcgcctaang ttcg 24

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
9 December 1999 (09.12.1999)

PCT

(10) International Publication Number
WO 99/62923 A3

- (51) International Patent Classification⁶: C07H 21/00, C07K 2/00, 14/52, A61K 31/70, 31/715, 38/00, 39/00
- (21) International Application Number: PCT/US99/12538
- (22) International Filing Date: 4 June 1999 (04.06.1999)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/088,310 5 June 1998 (05.06.1998) US
09/324,191 1 June 1999 (01.06.1999) US
- (71) Applicant (for all designated States except US): DY-NAVAX TECHNOLOGIES CORPORATION [US/US]; Suite 100, 717 Potter Street, Berkeley, CA 94710 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): SCHWARTZ, David [US/US]; 1544 Valleda Lane, Encinitas, CA 92024 (US).
- (74) Agents: POLIZZI, Catherine, M. et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).
- (81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— With international search report.
- (88) Date of publication of the international search report:
31 May 2001
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 99/62923 A3

(54) Title: IMMUNOSTIMULATORY OLIGONUCLEOTIDES WITH MODIFIED BASES AND METHODS OF USE THEREOF

(57) Abstract: Immunomodulatory oligonucleotide compositions are disclosed. These oligonucleotides comprise an immunostimulatory hexanucleotide sequence comprising a modified cytosine. These oligonucleotides can be administered in conjunction with an immunomodulatory peptide or antigen. Methods of modulating an immune response upon administration of the oligonucleotide comprising a modified immunostimulatory sequence are also disclosed.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 99/12538

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07H21/00 C07K2/00 C07K14/52 A61K31/70 A61K31/715
A61K38/00 A61K39/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07H C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, STRAND

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HARDIN, CHARLES C. ET AL: "Characterization of anti-Z-RNA polyclonal antibodies: epitope properties and recognition of Z-DNA" BIOCHEMISTRY (1988), 27(11), 4169-77, XP002129945 page 4169, right-hand column, last paragraph -page 4170, left-hand column, paragraph 3 page 4172, right-hand column, paragraph 2 -page 4173, left-hand column, paragraph 1 page 4174, left-hand column, paragraph 2 -right-hand column, paragraph 1 --- -/--	1-5, 24, 48

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

24 July 2000

Date of mailing of the international search report

11.08.00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Held, P

INTERNATIONAL SEARCH REPORT

In International Application No
PCT/US 99/12538

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		Relevant to claim No.
Category *	Citation of document, with indication, where appropriate, of the relevant passages	
X	<p>BRENNAN, CATHERINE A. ET AL: "The effects of base analog substitutions on the methylation by the EcoRI modification methylase of octadeoxyribonucleotides containing modified EcoRI recognition sequences" J. BIOL. CHEM. (1986), 261(16), 7279-86, XP002143307 page 7279 page 7284, right-hand column, paragraph 3 see RN 103549-62-8</p>	1,2,4,5
X	<p>JEAN, YUCH CHENG ET AL: "Z-DNA structure of a modified DNA hexamer at 1,4-.ANG. resolution: aminoethyl-5'-d(pCpGp'Br5C!pGpCpG)" BIOCHEMISTRY (1993), 32(1), 381-8 , XP002143308 page 381 -page 382, left-hand column, paragraph 1 see RN 145586-04-5</p>	1,2,4,5
X	<p>NGUYEN H ET AL: "Studies Towards the Design of a Modified GC Base Pair With Stability Similar to that of the AT Base Pair" TETRAHEDRON LETTERS,NL,ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 38, no. 23, 9 June 1997 (1997-06-09), pages 4083-4086, XP004065032 ISSN: 0040-4039 the whole document</p>	1,2,4,5
X	<p>FERRER, ELISENDA ET AL: "Preparation and Properties of Oligodeoxynucleotides Containing 5-Iodouracil and 5-Bromo- and 5-Iodocytosine" BIOCONJUGATE CHEM. (1997), 8(5), 757-761 , XP002143309 page 757, right-hand column, paragraph 1 page 760, left-hand column see RN 194096-69-0</p>	1,2,4,5
X	<p>DUTTA, RATNA ET AL: "Binding of the modified daunorubicin WP401 adjacent to a T-G base pair induces the reverse Watson-Crick conformation: crystal structures of the WP401-TGGCCG and WP401-CGG'br5C!CG complexes" NUCLEIC ACIDS RES. (1998), 26(12), 3001-3005, XP002143310 page 3001 -page 3002, left-hand column see RN 211176-10-2</p>	1,2,4,5
-/--		

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/12538

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>THERIAULT, N. Y. ET AL: "Studies on the base pair binding specificity of CC-1065 to oligomer duplexes" CHEM.-BIOL. INTERACT. (1988), 65(2), 187-201, XP000929239 page 188 -page 189 table I, entry 10 see RN 116193-94-3</p>	1,2,4,5
X	<p>YOON, CHUN ET AL: "Structure of an alternating-B DNA helix and its relationship to A-tract DNA" PROC. NATL. ACAD. SCI. U. S. A. (1988), 85(17), 6332-6, XP002143311 page 6336, left-hand column, paragraph 1 figure 6 see RN 117978-22-0</p>	1,2,4,5
A	<p>KRIEG A M ET AL: "CPG MOTIFS IN BACTERIAL DNA TRIGGER DIRECT B-CELL ACTIVATION" NATURE, GB, MACMILLAN JOURNALS LTD. LONDON, vol. 374, 6 April 1995 (1995-04-06), pages 546-549, XP000197060 ISSN: 0028-0836 page 546, right-hand column, paragraph 2 - paragraph 3 page 549, left-hand column, paragraph 1 table 1</p>	1,40
A	<p>GODDARD, AMANDA J. ET AL: "Synthesis of a phosphoramidite of 2'-deoxy-5,6-dihydro-5-azacytidine. Its potential application in the synthesis of DNA containing dihydro-5-aza an 5-azacytosine bases" TETRAHEDRON LETT. (1988), 29(15), 1767-70, XP002129946 page 1767, paragraph 1 page 1770</p>	1,40
A	<p>WO 89 09779 A (US GOVERNMENT) 19 October 1989 (1989-10-19) page 1, line 4 - line 9 scheme 1</p>	1,40
A	<p>US 4 948 882 A (RUTH JERRY L) 14 August 1990 (1990-08-14) column 4, line 22 - line 58 column 7</p>	1,40

-/--

INTERNATIONAL SEARCH REPORT

In: International Application No

PCT/US 99/12538

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>WO 98 55495 A (DYNAVAX TECHNOLOGIES CORP ;DINA DINO (US); ROMAN MARK (US); SCHWAR) 10 December 1998 (1998-12-10)</p> <p>page 1, line 10 - line 16 claims SEQ ID No 12, 15 and 16 -----</p>	<p>1,2,4-7, 9,11,12, 14,17, 18,20, 23-48</p>

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 99/12538

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 40-48 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

1-4 (partially), 5, 6-8 (partially), 9, 10, 11-13 (partially), 14-16, 17-19 (partially), 20-22, 23-28 (partially), 29-31, 32-48 (partially)
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1 (partially), 4 (partially), 6 (partially),
11 (partially), 17 (partially), 23-28 (partially),
32-48 (partially)

An immunomodulatory oligonucleotide comprising an immunostimulatory sequence comprising a modified cytosine characterized in that the modified cytosine is an azacytosine, in so far as it is neither a cyclocytosine nor a cytosine arabinoside; a composition containing such an oligonucleotide as well as the use of such a composition to modulate an immune response

2. Claims: 1 (partially), 4 (partially), 6 (partially),
11 (partially), 17 (partially), 23-28 (partially),
32-48 (partially)

An immunomodulatory oligonucleotide comprising an immunostimulatory sequence comprising a modified cytosine characterized in that the "modified cytosine" is an azapyrimidine (not an azacytosine), in so far as it is neither a cyclocytosine nor a cytosine arabinoside; a composition containing such an oligonucleotide as well as the use of such a composition to modulate an immune response

3. Claims: 1-4 (partially), 5, 6-8 (partially), 9, 10,
11-13 (partially), 14-16, 17-19 (partially),
20-22, 23-28 (partially), 29-31, 32-48 (partially)

An immunomodulatory oligonucleotide comprising an immunostimulatory sequence comprising a modified cytosine characterized in that the modified cytosine is 5-bromocytosine, in so far as it is neither a cyclocytosine nor a cytosine arabinoside; a composition containing such an oligonucleotide as well as the use of such a composition to modulate an immune response

4. Claims: 1-4 (partially), 6-8 (partially),
11-13 (partially), 17-19 (partially),
23-28 (partially), 32-48 (partially)

An immunomodulatory oligonucleotide comprising an immunostimulatory sequence comprising a modified cytosine characterized in that the "modified cytosine" is bromouracil, in so far as it is neither a cyclocytosine nor a cytosine arabinoside; a composition containing such an

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

oligonucleotide as well as the use of such a composition to modulate an immune response

5. Claims: 1-4 (partially), 6-8 (partially),
11-13 (partially), 17-19 (partially),
23-28 (partially), 32-48 (partially)

An immunomodulatory oligonucleotide comprising an immunostimulatory sequence comprising a modified cytosine characterized in that the "modified cytosine" is a bromopyrimidine (not a cytosine or an uracil), in so far as it is neither a cyclocytosine nor a cytosine arabinoside; a composition containing such an oligonucleotide as well as the use of such a composition to modulate an immune response

6. Claims: 1-4 (partially), 6-8 (partially),
11-13 (partially), 17-19 (partially),
23-28 (partially), 32-48 (partially)

An immunomodulatory oligonucleotide comprising an immunostimulatory sequence comprising a modified cytosine characterized in that the "modified cytosine" is a chloropyrimidine, in so far as it is neither a cyclocytosine nor a cytosine arabinoside; a composition containing such an oligonucleotide as well as the use of such a composition to modulate an immune response

7. Claims: 1-4 (partially), 6-8 (partially),
11-13 (partially), 17-19 (partially),
23-28 (partially), 32-48 (partially)

An immunomodulatory oligonucleotide comprising an immunostimulatory sequence comprising a modified cytosine characterized in that the "modified cytosine" is a fluoropyrimidine, in so far as it is neither a cyclocytosine nor a cytosine arabinoside; a composition containing such an oligonucleotide as well as the use of such a composition to modulate an immune response

8. Claims: 1-4 (partially), 6-8 (partially),
11-13 (partially), 17-19 (partially),
23-28 (partially), 32-48 (partially)

An immunomodulatory oligonucleotide comprising an immunostimulatory sequence comprising a modified cytosine characterized in that the "modified cytosine" is a 5-trifluoromethylpyrimidine, in so far as it is neither a

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

cyclocytosine nor a cytosine arabinoside; a composition containing such an oligonucleotide as well as the use of such a composition to modulate an immune response

9. Claims: 1-4 (partially), 6-8 (partially),
11-13 (partially), 17-19 (partially),
23-28 (partially), 32-48 (partially)

An immunomodulatory oligonucleotide comprising an immunostimulatory sequence comprising a modified cytosine characterized in that the "modified cytosine" is a 5,6-dihydropyrimidine, in so far as it is neither a cyclocytosine nor a cytosine arabinoside; a composition containing such an oligonucleotide as well as the use of such a composition to modulate an immune response

10. Claims: 1-4 (partially), 6-8 (partially),
11-13 (partially), 17-19 (partially),
23-28 (partially), 32-48 (partially)

An immunomodulatory oligonucleotide comprising an immunostimulatory sequence comprising a modified cytosine characterized in that the "modified cytosine" is a iodopyrimidine, in so far as it is neither a cyclocytosine nor a cytosine arabinoside; a composition containing such an oligonucleotide as well as the use of such a composition to modulate an immune response

11. Claims: 1-4 (partially), 6-8 (partially),
11-13 (partially), 17-19 (partially),
23-28 (partially), 32-48 (partially)

An immunomodulatory oligonucleotide comprising an immunostimulatory sequence comprising a modified cytosine characterized in that the "modified cytosine" is a nitropyrimidine, in so far as it is neither a cyclocytosine nor a cytosine arabinoside; a composition containing such an oligonucleotide as well as the use of such a composition to modulate an immune response

12. Claims: 1-4 (partially), 6-8 (partially),
11-13 (partially), 17-19 (partially),
23-28 (partially), 32-48 (partially)

An immunomodulatory oligonucleotide comprising an immunostimulatory sequence comprising a modified cytosine characterized in that the "modified cytosine" is a

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

hydroxyurea, in so far as it is neither a cyclocytosine nor a cytosine arabinoside; a composition containing such an oligonucleotide as well as the use of such a composition to modulate an immune response

13. Claims: 1-4 (partially), 6-8 (partially),
11-13 (partially), 17-19 (partially),
23-28 (partially), 32-48 (partially)

An immunomodulatory oligonucleotide comprising an immunostimulatory sequence comprising a modified cytosine characterized in that the modified cytosine is a cyclocytosine; a composition containing such an oligonucleotide as well as the use of such a composition to modulate an immune response

14. Claims: 1-4 (partially), 6-8 (partially),
11-13 (partially), 17-19 (partially),
23-28 (partially), 32-48 (partially)

An immunomodulatory oligonucleotide comprising an immunostimulatory sequence comprising a modified cytosine characterized in that the modified cytosine is a cytosine arabinoside; a composition containing such an oligonucleotide as well as the use of such a composition to modulate an immune response

15. Claims: 1-4 (partially), 6-8 (partially),
11-13 (partially), 17-19 (partially),
23-28 (partially), 32-48 (partially)

An immunomodulatory oligonucleotide comprising an immunostimulatory sequence comprising a modified cytosine characterized in that the "modified cytosine" is uracil; a composition containing such an oligonucleotide as well as the use of such a composition to modulate an immune response

16. Claims: 1-4 (partially), 6-8 (partially),
11-13 (partially), 17-19 (partially),
23-28 (partially); 32-48 (partially)

An immunomodulatory oligonucleotide comprising an immunostimulatory sequence comprising a modified cytosine characterized in that the "modified cytosine" is a pyrimidine not belonging to the groups of compounds mentioned in subjects 1-15; composition containing such an oligonucleotide as well as the use of such a composition to

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

modulate an immune response

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/12538

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 8909779	A	19-10-1989	US 5324831 A	28-06-1994
			AU 625295 B	09-07-1992
			AU 3368189 A	03-11-1989
			CA 1330960 A	26-07-1994
			JP 6092435 B	16-11-1994
			JP 3502577 T	13-06-1991
US 4948882	A	14-08-1990	US 5541313 A	30-07-1996
			US 5668266 A	16-09-1997
			US 5817786 A	06-10-1998
			AU 596068 B	26-04-1990
			AU 2813984 A	10-09-1984
			DE 3482113 D	07-06-1990
			DK 502184 A	19-12-1984
			EP 0135587 A	03-04-1985
			JP 2542453 B	09-10-1996
			JP 3086897 A	11-04-1991
			NO 844196 A	19-10-1984
			WO 8403285 A	30-08-1984
WO 9855495	A	10-12-1998	AU 7811398 A	21-12-1998
			AU 7817898 A	21-12-1998
			EP 1003850 A	31-05-2000
			EP 0986572 A	22-03-2000
			WO 9855609 A	10-12-1998